Guide RNA, gene editing system and use thereof

By targeting and reducing the expression of ADRB2 and AQP1 RNA using the CRISPR/Cas system, this study overcomes the limitations of existing glaucoma treatments and provides a novel gene-editing method to regulate intraocular pressure and alleviate glaucoma symptoms.

WO2024230837A1PCT designated stage expired Publication Date: 2024-11-14GUANGZHOU REFORGENE MEDICINE CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092680
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-11
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current glaucoma treatments primarily alleviate symptoms by lowering intraocular pressure, but there are still issues with limited effective drugs and poor long-term efficacy. In particular, the roles of β-adrenergic receptor 2 (ADRB2) and aquaporin 1 (AQP1) in glaucoma have not been fully utilized.

Method used

Using a gene editing system, the translation of ADRB2 and AQP1 RNA is targeted and knocked down or inhibited through the CRISPR/Cas system, thereby reducing their expression levels, regulating intraocular pressure, reducing apoptosis of retinal ganglion cells, and alleviating glaucoma symptoms.

Benefits of technology

This method effectively reduces the expression of ADRB2 and AQP1 RNA, decreases intraocular pressure, and slows the progression of glaucoma, providing a novel gene-editing approach to treat glaucoma and avoiding the limitations of traditional drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024092680-FTAPPB-I100001
    Figure PCTCN2024092680-FTAPPB-I100001
  • Figure PCTCN2024092680-FTAPPB-I100002
    Figure PCTCN2024092680-FTAPPB-I100002
  • Figure PCTCN2024092680-FTAPPB-I100003
    Figure PCTCN2024092680-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a guide RNA and a gene editing system containing same. The gene editing system targets and knocks down the level of ADRB2 RNA or inhibits the translation thereof, and / or knocks down the level of AQP1 RNA or inhibits the translation thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Guide RNA, gene editing systems and their applications

[0001] This application claims the benefit of Chinese Patent Application No. 2023105339853, filed May 11, 2023. This application incorporates the entirety of the aforementioned Chinese Patent Application. Technical Field

[0002] The present invention belongs to the field of gene editing technology, and specifically relates to a gene editing system and its application. Background Art

[0003] Glaucoma affects approximately 70 million people worldwide, with approximately 10% of patients experiencing binocular visual field loss. Glaucoma is one of the leading causes of visual field loss.

[0004] Glaucoma is a neurodegenerative disease characterized by the apoptosis of retinal ganglion cells (RGCs) and the degeneration of their axons. Ganglion cell apoptosis is primarily related to intraocular pressure (IOP). IOP is primarily maintained by aqueous humor. Lesions in the ciliary body (CB), the aqueous humor's production tissue, and the trabecular meshwork (TM), its primary drainage system, can disrupt aqueous humor circulation, ultimately leading to elevated IOP, compression of RGCs, and ultimately irreversible visual field loss.

[0005] Currently, lowering intraocular pressure (IOP) remains a common treatment for glaucoma. Five main classes of IOP-lowering drugs are currently available on the market: α-adrenergic agonists, β-adrenergic antagonists, cholinergic agonists, prostaglandins, and carbonic anhydrase inhibitors. These are primarily administered as eye drops.

[0006] β-Adrenergic antagonists, such as timolol maleate, are commonly used to lower intraocular pressure. β-Adrenergic antagonists primarily reduce intraocular pressure by decreasing aqueous humor production, primarily targeting the β-adrenergic receptor 2 (ADRB2). ADRB2 is abundantly expressed in the non-pigmented epithelial cells of the ciliary body. β-Adrenergic receptors are also present in the corneal endothelium, lens epithelium, choroid, and extraocular muscles. The majority of β-adrenergic receptors detected in the eye are of the β2 type.

[0007] The CRISPR / Cas (clustered regularly interspaced short palindromic repeats / CRISPR-associated proteins) system is currently the most widely used gene editing technology.

[0008] Summary of the Invention

[0009] A first aspect of the present disclosure provides use of a gene editing system in preparing a medicament for diagnosing, treating or preventing glaucoma, wherein the gene editing system:

[0010] (I) knocking down ADRB2 RNA levels or inhibiting ADRB2 RNA translation; or

[0011] (II) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA, and knocking down the level of AQP1 RNA or inhibiting the translation of AQP1 RNA.

[0012] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels or inhibits the translation of ADRB2 RNA.

[0013] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels.

[0014] In some embodiments of the present disclosure, the gene editing system inhibits translation of ADRB2 RNA.

[0015] In some embodiments of the present disclosure, the gene editing system knocks down the level of ADRB2 RNA or inhibits the translation of ADRB2 RNA, and knocks down the level of AQP1 RNA or inhibits the translation of AQP1 RNA.

[0016] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels and knocks down AQP1 RNA levels.

[0017] In some embodiments of the present disclosure, the gene editing system inhibits translation of ADRB2 RNA and inhibits translation of AQP1 RNA.

[0018] The gene editing system disclosed herein targets and knocks down RNA or inhibits RNA translation without changing genomic DNA.

[0019] In some embodiments of the present disclosure, the gene editing system comprises:

[0020] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease,

[0021] and optional

[0022] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease;

[0023] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0024] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0025] In some embodiments of the present disclosure, the gene editing system comprises:

[0026] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease;

[0027] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0028] In some embodiments of the present disclosure, the gene editing system comprises:

[0029] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease,

[0030] as well as

[0031] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease;

[0032] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0033] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0034] In some embodiments of the present disclosure, the gene editing system comprises:

[0035] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA,

[0036] and optional

[0037] (II) a second guide RNA comprising a guide sequence that hybridizes to the AQP1 RNA, and a second nuclease guided by the RNA;

[0038] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0039] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0040] In some embodiments of the present disclosure, the gene editing system comprises:

[0041] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA;

[0042] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0043] In some embodiments of the present disclosure, the gene editing system comprises:

[0044] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA,

[0045] as well as

[0046] (II) a second guide RNA comprising a guide sequence that hybridizes to the AQP1 RNA, and a second nuclease guided by the RNA;

[0047] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0048] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0049] In some embodiments of the present disclosure, the gene editing system comprises:

[0050] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA,

[0051] and optional

[0052] (II) a polynucleotide sequence encoding a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA, and a polynucleotide sequence encoding a second nuclease guided by the RNA;

[0053] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0054] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0055] In some embodiments of the present disclosure, the gene editing system comprises:

[0056] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA;

[0057] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0058] In some embodiments of the present disclosure, the gene editing system comprises:

[0059] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA,

[0060] as well as

[0061] (II) a polynucleotide sequence encoding a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA, and a polynucleotide sequence encoding a second nuclease guided by the RNA;

[0062] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0063] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0064] In some embodiments of the present disclosure, the ADRB2 RNA is a mammalian mature mRNA; and / or the AQP1 RNA is a mammalian pre-mRNA and / or mature mRNA.

[0065] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and / or the AQP1 RNA is human pre-mRNA and / or mature mRNA.

[0066] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human pre-mRNA and / or mature mRNA.

[0067] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human pre-mRNA.

[0068] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human mature mRNA.

[0069] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA, and the sequence of the human mature mRNA is shown in SEQ ID NO: 684.

[0070] In some embodiments of the present disclosure, the AQP1 RNA is human pre-mRNA, and the human pre-mRNA sequence is shown in SEQ ID NO: 707.

[0071] In some embodiments of the present disclosure, the AQP1 RNA is human mature mRNA, and the sequence of the human mature mRNA is shown in SEQ ID NO: 703.

[0072] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and / or the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0073] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA.

[0074] In some embodiments of the present disclosure, the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0075] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0076] In some embodiments of the present disclosure, after contacting the first complex with a cell containing ADRB2 RNA, the level of the ADRB2 RNA or ADRB2 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%;

[0077] and / or

[0078] Upon contacting the second complex with a cell comprising AQP1 RNA, the level of AQP1 RNA or AQP1 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0079] In some embodiments of the present disclosure, after contacting the first complex with a cell containing ADRB2 RNA, the level of ADRB2 RNA in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

[0080] In some embodiments of the present disclosure, after the first complex is contacted with a cell containing ADRB2 RNA, the level of the ADRB2 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

[0081] In some embodiments of the disclosure, upon contacting the second complex with a cell comprising AQP1 RNA, the level of AQP1 RNA in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0082] In some embodiments of the present disclosure, upon contacting the second complex with a cell comprising AQP1 RNA, the level of the AQP1 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0083] In some embodiments of the present disclosure, the cell is a eukaryotic cell. In some embodiments of the present disclosure, the cell is a mammalian cell. In some embodiments of the present disclosure, the cell is a human cell.

[0084] The reduction in the RNA level can be tested using conventional methods in the art; including but not limited to qPCR methods, such as RT-qPCR methods. The target RNA (the ADRB2 RNA or the AQP1 RNA) level of untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be tested as a negative control, and the target RNA knockdown level of the experimental group compared to the negative control is calculated. The experimental group and the negative control group can be edited using the same Cas protein (e.g., by expressing the same Cas protein) and gRNA containing different guide sequences to compare the difference in target RNA levels; for example, the experimental group is edited using C13-2 and a gRNA as claimed in the present disclosure, and the negative control group is edited using C13-2 and a gRNA targeting, for example, a bacterial genome. The experimental group can also be compared with known editing tools, for example, compared with the CasRx+gRNA editing tool.

[0085] In some embodiments of the present disclosure, the number of off-target genes when the complex binds to and cuts the target RNA (the ADRB2 RNA or the AQP1 RNA) is less than 40, less than 35, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2 or less than 1. The number of off-target genes can be determined by conventional methods in the art. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set whose expression is downregulated by RNA sequencing and the off-target gene set predicted by the program. Off-target genes can be predicted using off-target gene prediction programs known in the art under conventional parameter settings. As a non-limiting example, the program predicts a target gene using the EMBOSS-water program in the whole genome and whole cDNA sequence of the target species (e.g., Homo sapiens or Mus musculus, etc.), setting the parameters to gap_extend = 0.5 & gap_extend = 10, using the forward and reverse strands of the gRNA guide sequence for alignment, filtering the prediction results, and obtaining predicted potential target genes (including on-target genes and / or off-target genes).

[0086] The reduction in the level of protein encoded by the target RNA (the ADRB2 RNA or the AQP1 RNA) can be tested using conventional methods in the art, including but not limited to ELISA and Western Blotting. Untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be used as negative controls, and the level of ADRB2 protein or AQP1 protein in the experimental group is calculated compared to the negative control group.

[0087] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in SEQ ID NO: 684.

[0088] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 1-2013, or nucleotides 222-1463 of the sequence of SEQ ID NO: 684 (full length, CDS region, respectively).

[0089] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 222-1463 of the sequence set forth in SEQ ID NO: 684.

[0090] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has 100% sequence identity with nucleotides 222-1463 of the sequence shown in SEQ ID NO: 684.

[0091] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 703.

[0092] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 1-2754, or nucleotides 58-867 of SEQ ID NO: 703 (full length, CDS region, respectively).

[0093] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 58-867 of SEQ ID NO: 703.

[0094] In some embodiments of the present disclosure, the guide sequence of the second guide RNA has 100% sequence identity to nucleotides 58-867 of SEQ ID NO: 703.

[0095] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

[0096] In some embodiments of the present disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in SEQ ID NO: 704.

[0097] In some embodiments of the present disclosure, the guide sequence of the first guide RNA is the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

[0098] In some embodiments of the present disclosure, the guide sequence of the second guide RNA is the sequence shown in SEQ ID NO: 704.

[0099] In some embodiments of the disclosure, the first guide sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 7, 8, 10, 17, 18, 709, and 710.

[0100] In some embodiments of the disclosure, the first guide sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710.

[0101] In some embodiments of the disclosure, the first guide sequence has 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710.

[0102] In some embodiments of the present disclosure, the first guide sequence is any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710. (Specific high-activity sequence)

[0103] In some embodiments of the present disclosure, the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with the first nuclease guided by the RNA; and / or

[0104] The second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with a second RNA-guided nuclease.

[0105] In some embodiments of the present disclosure, the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with a first nuclease guided by the RNA.

[0106] In some embodiments of the present disclosure, the second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with the RNA-guided second nuclease.

[0107] In some embodiments of the present disclosure, the RNA-guided first nuclease is a Cas protein; optionally, the RNA-guided first nuclease is a Cas9 protein, a Cas12 protein, or a Cas13 protein; further optionally, the RNA-guided first nuclease is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein, or a Cas13j protein.

[0108] In some embodiments of the present disclosure, the RNA-guided second nuclease is a Cas protein; optionally, the RNA-guided second nuclease is a Cas9 protein, a Cas12 protein, or a Cas13 protein; further optionally, the RNA-guided second nuclease is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein, or a Cas13j protein.

[0109] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 700.

[0110] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:700.

[0111] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:708.

[0112] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:708.

[0113] In some embodiments of the present disclosure, the first RNA-guided nuclease is the same as or different from the second RNA-guided nuclease.

[0114] In some embodiments of the present disclosure, the RNA-guided first nuclease and / or the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0115] In some embodiments of the present disclosure, the RNA-guided first nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0116] In some embodiments of the present disclosure, the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0117] In some embodiments of the present disclosure, the subcellular localization signal is a nuclear localization signal and / or a nuclear export signal sequence.

[0118] In some embodiments of the present disclosure, the subcellular localization signal is a mitochondrial localization signal or a chloroplast localization signal sequence.

[0119] In some embodiments of the present disclosure, the polynucleotide sequence encoding the first RNA-guided nuclease is linked to a regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is linked to a regulatory sequence 2 that regulates its expression; and / or

[0120] The polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0121] In some embodiments of the present disclosure, the polynucleotide sequence encoding the first RNA-guided nuclease is connected to a regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to a regulatory sequence 2 that regulates its expression.

[0122] In some embodiments of the present disclosure, the polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0123] In some embodiments of the present disclosure, the regulatory sequence 1 that regulates the expression of the first RNA-guided nuclease is the same as or different from the regulatory sequence 3 that regulates the expression of the second RNA-guided nuclease.

[0124] In some embodiments of the present disclosure, the regulatory sequence 2 that regulates the expression of the first guide RNA is the same as or different from the regulatory sequence 4 that regulates the expression of the second guide RNA.

[0125] In some embodiments of the present disclosure, the regulatory sequence is a promoter sequence. In some embodiments of the present disclosure, the regulatory sequence is an enhancer sequence. In some embodiments of the present disclosure, the regulatory sequence is a promoter and enhancer sequence.

[0126] In some embodiments of the present disclosure, the regulatory sequence is selected from the group consisting of a CMV promoter, a CMV enhancer, a CBh promoter, a U6 promoter, and an eye-specific promoter.

[0127] In some embodiments of the present disclosure, the gene editing system comprises:

[0128] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first Cas13 protein or a polynucleotide sequence encoding the first Cas13 protein,

[0129] and optional

[0130] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and a second Cas13 protein guided by the RNA or a polynucleotide sequence encoding the second Cas13 protein;

[0131] The first guide RNA is capable of forming a first CRISPR complex with the first Cas13 protein and guiding the complex sequence to specifically bind to and cleave ADRB2 RNA;

[0132] The second guide RNA is capable of forming a second CRISPR complex with the second Cas13 protein and guiding the complex sequence to specifically bind to and cut AQP1 RNA.

[0133] In some embodiments, the coding sequence is linked to regulatory sequences.

[0134] In some embodiments, the polynucleotide sequence encoding the first Cas13 protein is connected to the regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to the regulatory sequence 2 that regulates its expression;

[0135] The polynucleotide sequence encoding the second Cas13 protein is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0136] In some embodiments, the first guide RNA and the second guide RNA are expressed in tandem under the control of the same regulatory sequence. Further, the tandem expression obtains a crRNA precursor (pre-cRNA), which is then processed by the first Cas13 protein or the second Cas13 protein to obtain a mature guide RNA molecule.

[0137] In some embodiments, the first Cas13 protein and the second Cas13 protein are identical.In some embodiments, regulatory sequence 1 and regulatory sequence 3 are identical.

[0138] In some embodiments, the polynucleotide sequence encoding the first guide RNA and the polynucleotide sequence encoding the RNA-guided first nuclease are located on the same vector.

[0139] In some embodiments, the polynucleotide sequence encoding the second guide RNA and the polynucleotide sequence encoding the second nuclease guided by the RNA are located on the same vector.

[0140] In some embodiments, the polynucleotide sequence encoding the first guide RNA and the polynucleotide sequence encoding the second guide RNA are located on the same vector.

[0141] In some embodiments, the polynucleotide sequence encoding the first RNA-guided nuclease and the polynucleotide sequence encoding the second RNA-guided nuclease are located on the same vector.

[0142] In some embodiments of the present disclosure, the gene editing system is introduced into a cell or cell-free system in any of the following ways: (i) as mRNA encoding an RNA-guided nuclease and a guide RNA, (ii) as part of a single vector or plasmid, or divided into multiple vectors or plasmids, (iii) as separate RNA-guided nucleases and guide RNAs, or (iv) as an RNP complex of an RNA-guided nuclease and a guide RNA.

[0143] A second aspect of the present disclosure provides a gene editing system, characterized in that the gene editing system:

[0144] (I) knocking down ADRB2 RNA levels or inhibiting ADRB2 RNA translation; or

[0145] (II) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA, and knocking down the level of AQP1 RNA or inhibiting the translation of AQP1 RNA.

[0146] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels or inhibits the translation of ADRB2 RNA.

[0147] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels.

[0148] In some embodiments of the present disclosure, the gene editing system inhibits translation of ADRB2 RNA.

[0149] In some embodiments of the present disclosure, the gene editing system knocks down the level of ADRB2 RNA or inhibits the translation of ADRB2 RNA, and knocks down the level of AQP1 RNA or inhibits the translation of AQP1 RNA.

[0150] In some embodiments of the present disclosure, the gene editing system knocks down ADRB2 RNA levels and knocks down AQP1 RNA levels.

[0151] In some embodiments of the present disclosure, the gene editing system inhibits translation of ADRB2 RNA and inhibits translation of AQP1 RNA.

[0152] The gene editing system disclosed herein targets and knocks down RNA or inhibits RNA translation without changing genomic DNA.

[0153] In some embodiments of the present disclosure, the gene editing system comprises:

[0154] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease,

[0155] and optional

[0156] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease;

[0157] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0158] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0159] In some embodiments of the present disclosure, the gene editing system comprises:

[0160] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease;

[0161] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0162] In some embodiments of the present disclosure, the gene editing system comprises:

[0163] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease,

[0164] as well as

[0165] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease;

[0166] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0167] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0168] In some embodiments of the present disclosure, the gene editing system comprises:

[0169] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA,

[0170] and optional

[0171] (II) a second guide RNA comprising a guide sequence that hybridizes to the AQP1 RNA, and a second nuclease guided by the RNA;

[0172] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0173] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0174] In some embodiments of the present disclosure, the gene editing system comprises:

[0175] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA;

[0176] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0177] In some embodiments of the present disclosure, the gene editing system comprises:

[0178] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a first nuclease guided by the RNA,

[0179] as well as

[0180] (II) a second guide RNA comprising a guide sequence that hybridizes to the AQP1 RNA, and a second nuclease guided by the RNA;

[0181] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0182] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0183] In some embodiments of the present disclosure, the gene editing system comprises:

[0184] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA,

[0185] and optional

[0186] (II) a polynucleotide sequence encoding a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA, and a polynucleotide sequence encoding a second nuclease guided by the RNA;

[0187] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0188] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0189] In some embodiments of the present disclosure, the gene editing system comprises:

[0190] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA;

[0191] The first guide RNA is capable of forming a first complex with the first nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0192] In some embodiments of the present disclosure, the gene editing system comprises:

[0193] (I) a polynucleotide sequence encoding a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA, and a polynucleotide sequence encoding a first nuclease guided by the RNA,

[0194] as well as

[0195] (II) a polynucleotide sequence encoding a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA, and a polynucleotide sequence encoding a second nuclease guided by the RNA;

[0196] The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA;

[0197] The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

[0198] In some embodiments of the present disclosure, the ADRB2 RNA is a mammalian mature mRNA; and / or the AQP1 RNA is a mammalian pre-mRNA and / or mature mRNA.

[0199] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and / or the AQP1 RNA is human pre-mRNA and / or mature mRNA.

[0200] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human pre-mRNA and / or mature mRNA.

[0201] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human pre-mRNA.

[0202] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA; and the AQP1 RNA is human mature mRNA.

[0203] In some embodiments of the present disclosure, the ADRB2 RNA is human mature mRNA, and the sequence of the human mature mRNA is shown in SEQ ID NO: 684.

[0204] In some embodiments of the present disclosure, the AQP1 RNA is human pre-mRNA, and the human pre-mRNA sequence is shown in SEQ ID NO: 707.

[0205] In some embodiments of the present disclosure, the AQP1 RNA is human mature mRNA, and the sequence of the human mature mRNA is shown in SEQ ID NO: 703.

[0206] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and / or the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0207] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA.

[0208] In some embodiments of the present disclosure, the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0209] In some embodiments of the present disclosure, the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

[0210] In some embodiments of the present disclosure, after contacting the first complex with a cell containing ADRB2 RNA, the level of the ADRB2 RNA or ADRB2 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%;

[0211] and / or

[0212] Upon contacting the second complex with a cell comprising AQP1 RNA, the level of AQP1 RNA or AQP1 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0213] In some embodiments of the present disclosure, after contacting the first complex with a cell containing ADRB2 RNA, the level of ADRB2 RNA in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

[0214] In some embodiments of the present disclosure, after the first complex is contacted with a cell containing ADRB2 RNA, the level of the ADRB2 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.

[0215] In some embodiments of the disclosure, upon contacting the second complex with a cell comprising AQP1 RNA, the level of AQP1 RNA in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0216] In some embodiments of the present disclosure, upon contacting the second complex with a cell comprising AQP1 RNA, the level of the AQP1 protein in the cell is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0217] In some embodiments of the present disclosure, the cell is a eukaryotic cell. In some embodiments of the present disclosure, the cell is a mammalian cell. In some embodiments of the present disclosure, the cell is a human cell.

[0218] The reduction in the RNA level can be tested using conventional methods in the art; including but not limited to qPCR methods, such as RT-qPCR methods. The target RNA (the ADRB2 RNA or the AQP1 RNA) level of untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be tested as a negative control, and the target RNA knockdown level of the experimental group compared to the negative control is calculated. The experimental group and the negative control group can be edited using the same Cas protein (e.g., by expressing the same Cas protein) and gRNA containing different guide sequences to compare the difference in target RNA levels; for example, the experimental group is edited using C13-2 and a gRNA as claimed in the present disclosure, and the negative control group is edited using C13-2 and a gRNA targeting, for example, a bacterial genome. The experimental group can also be compared with known editing tools, for example, compared with the CasRx+gRNA editing tool.

[0219] In some embodiments of the present disclosure, the number of off-target genes when the complex binds to and cuts the target RNA (the ADRB2 RNA or the AQP1 RNA) is less than 40, less than 35, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2 or less than 1. The number of off-target genes can be determined by conventional methods in the art. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set whose expression is downregulated by RNA sequencing and the off-target gene set predicted by the program. Off-target genes can be predicted using off-target gene prediction programs known in the art under conventional parameter settings. As a non-limiting example, the program predicts a target gene using the EMBOSS-water program in the whole genome and whole cDNA sequence of the target species (e.g., Homo sapiens or Mus musculus, etc.), setting the parameters to gap_extend = 0.5 & gap_extend = 10, using the forward and reverse strands of the gRNA guide sequence for alignment, filtering the prediction results, and obtaining predicted potential target genes (including on-target genes and / or off-target genes).

[0220] The reduction in the level of protein encoded by the target RNA (the ADRB2 RNA or the AQP1 RNA) can be tested using conventional methods in the art, including but not limited to ELISA and Western Blotting. Untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be used as negative controls, and the level of ADRB2 protein or AQP1 protein in the experimental group is calculated compared to the negative control group.

[0221] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in SEQ ID NO: 684.

[0222] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 1-2013, or nucleotides 222-1463 of the sequence set forth in SEQ ID NO: 684.

[0223] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 222-1463 of the sequence set forth in SEQ ID NO: 684.

[0224] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has 100% sequence identity with nucleotides 222-1463 of the sequence shown in SEQ ID NO: 684.

[0225] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 703.

[0226] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 1-2754, or nucleotides 58-867 of SEQ ID NO: 703.

[0227] In some embodiments of the disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 58-867 of SEQ ID NO: 703.

[0228] In some embodiments of the present disclosure, the guide sequence of the second guide RNA has 100% sequence identity to nucleotides 58-867 of SEQ ID NO: 703.

[0229] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

[0230] In some embodiments of the present disclosure, the guide sequence of the second guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in SEQ ID NO: 704.

[0231] In some embodiments of the present disclosure, the guide sequence of the first guide RNA is the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

[0232] In some embodiments of the present disclosure, the guide sequence of the second guide RNA is the sequence shown in SEQ ID NO: 704.

[0233] In some embodiments of the disclosure, the first guide sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 7, 8, 10, 17, 18, 709, and 710.

[0234] In some embodiments of the disclosure, the first guide sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710.

[0235] In some embodiments of the disclosure, the first guide sequence has 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710.

[0236] In some embodiments of the present disclosure, the first guide sequence is the sequence shown in any one of SEQ ID NOs: 8, 10, 17, 18, 709, and 710.

[0237] In some embodiments of the present disclosure, the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with the first nuclease guided by the RNA; and / or

[0238] The second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with a second RNA-guided nuclease.

[0239] In some embodiments of the present disclosure, the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with a first nuclease guided by the RNA.

[0240] In some embodiments of the present disclosure, the second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with the RNA-guided second nuclease.

[0241] In some embodiments of the present disclosure, the RNA-guided first nuclease is a Cas protein; optionally, the RNA-guided first nuclease is a Cas9 protein, a Cas12 protein, or a Cas13 protein; further optionally, the RNA-guided first nuclease is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein, or a Cas13j protein.

[0242] In some embodiments of the present disclosure, the RNA-guided second nuclease is a Cas protein; optionally, the RNA-guided second nuclease is a Cas9 protein, a Cas12 protein, or a Cas13 protein; further optionally, the RNA-guided second nuclease is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein, or a Cas13j protein.

[0243] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 700.

[0244] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:700.

[0245] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:708.

[0246] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:708.

[0247] In some embodiments of the present disclosure, the first RNA-guided nuclease is the same as or different from the second RNA-guided nuclease.

[0248] In some embodiments of the present disclosure, the RNA-guided first nuclease and / or the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0249] In some embodiments of the present disclosure, the RNA-guided first nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0250] In some embodiments of the present disclosure, the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0251] In some embodiments of the present disclosure, the subcellular localization signal is a nuclear localization signal and / or a nuclear export signal sequence.

[0252] In some embodiments of the present disclosure, the subcellular localization signal is a mitochondrial localization signal or a chloroplast localization signal sequence.

[0253] In some embodiments of the present disclosure, the polynucleotide sequence encoding the first RNA-guided nuclease is linked to a regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is linked to a regulatory sequence 2 that regulates its expression; and / or

[0254] The polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0255] In some embodiments of the present disclosure, the polynucleotide sequence encoding the first RNA-guided nuclease is connected to a regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to a regulatory sequence 2 that regulates its expression.

[0256] In some embodiments of the present disclosure, the polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0257] In some embodiments of the present disclosure, the regulatory sequence 1 that regulates the expression of the first RNA-guided nuclease is the same as or different from the regulatory sequence 3 that regulates the expression of the second RNA-guided nuclease.

[0258] In some embodiments of the present disclosure, the regulatory sequence 2 that regulates the expression of the first guide RNA is the same as or different from the regulatory sequence 4 that regulates the expression of the second guide RNA.

[0259] In some embodiments of the present disclosure, the regulatory sequence is a promoter sequence. In some embodiments of the present disclosure, the regulatory sequence is an enhancer sequence. In some embodiments of the present disclosure, the regulatory sequence is a promoter and enhancer sequence.

[0260] In some embodiments of the present disclosure, the regulatory sequence is selected from the group consisting of a CMV promoter, a CMV enhancer, a CBh promoter, a U6 promoter, and an eye-specific promoter.

[0261] In some embodiments of the present disclosure, the gene editing system comprises:

[0262] (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and a first Cas13 protein or a polynucleotide sequence encoding the first Cas13 protein,

[0263] and optional

[0264] (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and a second Cas13 protein guided by the RNA or a polynucleotide sequence encoding the second Cas13 protein;

[0265] The first guide RNA is capable of forming a first CRISPR complex with the first Cas13 protein and guiding the complex sequence to specifically bind to and cleave ADRB2 RNA;

[0266] The second guide RNA is capable of forming a second CRISPR complex with the second Cas13 protein and guiding the complex sequence to specifically bind to and cut AQP1 RNA.

[0267] In some embodiments, the coding sequence is linked to regulatory sequences.

[0268] In some embodiments, the polynucleotide sequence encoding the first Cas13 protein is connected to the regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to the regulatory sequence 2 that regulates its expression;

[0269] The polynucleotide sequence encoding the second Cas13 protein is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

[0270] In some embodiments, the first guide RNA and the second guide RNA are expressed in tandem under the control of the same regulatory sequence. Further, the tandem expression obtains a crRNA precursor (pre-cRNA), which is then processed by the first Cas13 protein or the second Cas13 protein to obtain a mature guide RNA molecule.

[0271] In some embodiments, the first Cas13 protein and the second Cas13 protein are identical.In some embodiments, regulatory sequence 1 and regulatory sequence 3 are identical.

[0272] In some embodiments, the polynucleotide sequence encoding the first guide RNA and the polynucleotide sequence encoding the RNA-guided first nuclease are located on the same vector.

[0273] In some embodiments, the polynucleotide sequence encoding the second guide RNA and the polynucleotide sequence encoding the second nuclease guided by the RNA are located on the same vector.

[0274] In some embodiments, the polynucleotide sequence encoding the first guide RNA and the polynucleotide sequence encoding the second guide RNA are located on the same vector.

[0275] In some embodiments, the polynucleotide sequence encoding the first RNA-guided nuclease and the polynucleotide sequence encoding the second RNA-guided nuclease are located on the same vector.

[0276] In some embodiments of the present disclosure, the gene editing system is introduced into a cell or cell-free system in any of the following ways: (i) as mRNA encoding an RNA-guided nuclease and a guide RNA, (ii) as part of a single vector or plasmid, or divided into multiple vectors or plasmids, (iii) as separate RNA-guided nucleases and guide RNAs, or (iv) as an RNP complex of an RNA-guided nuclease and a guide RNA.

[0277] A third aspect of the present disclosure provides a gene editing system guide RNA (gRNA), characterized in that it comprises a guide sequence that hybridizes with ADRB2 RNA.

[0278] In some embodiments of the present disclosure, the ADRB2 RNA is a mammalian mature mRNA. In some embodiments of the present disclosure, the ADRB2 RNA is a human mature mRNA.

[0279] In some embodiments of the present disclosure, the ADRB2 RNA sequence is the sequence shown in SEQ ID NO: 684.

[0280] In some embodiments of the disclosure, the guide sequence has at least 80% sequence identity to the sequence of SEQ ID NO: 684. In some embodiments of the disclosure, the guide sequence has at least 85%, at least 90%, at least 95%, or 100% sequence identity to the sequence of SEQ ID NO: 684. Further, in some embodiments of the disclosure, the guide sequence has 100% sequence identity to the target RNA.

[0281] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to nucleotides 222-1463 of the sequence set forth in SEQ ID NO: 684.

[0282] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

[0283] In some embodiments of the present disclosure, the guide sequence of the first guide RNA has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-20.

[0284] In some embodiments of the disclosure, the first guide sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 7, 8, 10, 17, 18, 709, and 710.

[0285] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with an RNA-guided nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

[0286] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with the nuclease and guiding the complex to bind to and cleave the ADRB2 RNA.

[0287] In some embodiments of the present disclosure, the complex reduces the level of the ADRB2 RNA in a mammal (eg, a human).

[0288] In some embodiments of the present disclosure, after contacting the complex with a cell containing ADRB2 RNA, the level of the ADRB2 RNA in the cell is reduced, for example, the level of the target RNA in a cell expressing the target RNA.

[0289] In some embodiments of the present disclosure, the complex reduces the level of ADRB2 RNA in the cell by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. The reduction in ADRB2 RNA levels can be tested using conventional methods in the art, including but not limited to the qPCR method described in the Examples, and untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be used as negative controls to calculate the level of ADRB2 RNA knockdown in the experimental group compared to the negative control.

[0290] In some embodiments of the present invention, the number of off-target genes when the complex binds to and cuts the ADRB2 RNA is less than 40, less than 35, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2 or less than 1. The number of off-target genes can be determined by conventional methods in the art. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program. As a non-limiting example, the program predicts the target gene using the EMBOSS-water program in the whole genome and full cDNA sequence of the target species (Homo sapiens / Mus musculus), setting the parameters to gap_extend=0.5&gap_extend=10, using the forward and reverse strands of the gRNA guide sequence for alignment, filtering the prediction results, and obtaining predicted potential target genes (including on-target genes and off-target genes).

[0291] In some embodiments of the present disclosure, the complex reduces the level of the protein encoded by the ADRB2 RNA in an animal (eg, a human).

[0292] In some embodiments of the present disclosure, upon contact of the complex with a cell containing the target RNA, the level of the protein encoded by the ADRB2 RNA in the cell is reduced. In some embodiments of the present disclosure, the protein encoded by the ADRB2 RNA is ADRB2 protein. In some embodiments of the present disclosure, the complex reduces the level of the ADRB2 protein in the cell.

[0293] In some embodiments of the present disclosure, the complex reduces the level of ADRB2 protein in cells by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. The reduction in the level of protein encoded by the ADRB2 RNA can be tested using conventional methods in the art, including but not limited to ELISA and Western Blotting. Untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be used as negative controls to calculate the level of ADRB2 protein knockdown in the experimental group compared to the negative control group.

[0294] In some embodiments of the present disclosure, the guide RNA comprises a guide sequence and a backbone sequence, wherein the backbone sequence interacts with the RNA-guided nuclease. In some embodiments of the present disclosure, the backbone sequence is a direct repeat sequence (DR).

[0295] The fourth aspect of the present disclosure provides an isolated nucleic acid, characterized in that it encodes the guide RNA according to any one of the present disclosures.

[0296] The fifth aspect of the present disclosure provides a vector, comprising a polynucleotide sequence encoding the guide RNA according to any one of the present disclosure, and a regulatory sequence for regulating the expression of the guide RNA.

[0297] In some embodiments of the present disclosure, the vector is an adeno-associated virus vector.

[0298] In some embodiments of the present disclosure, the regulatory sequence is a promoter sequence. In some embodiments of the present disclosure, the regulatory sequence is an enhancer sequence. In some embodiments of the present disclosure, the regulatory sequence is a promoter and enhancer sequence.

[0299] In some embodiments of the present disclosure, the regulatory sequence is selected from the group consisting of a CMV promoter, a CMV enhancer, a CBh promoter, a U6 promoter, and an eye-specific promoter.

[0300] In some embodiments of the present disclosure, the eye-specific promoter is selected from the group consisting of: a retinoschisis protein promoter, a K12 promoter, a rhodopsin promoter, a rod-specific promoter, a cone-specific promoter, a rhodopsin kinase promoter, a GRK1 promoter, an interphotoreceptor retinoid-binding protein proximal (IRBP) promoter, and an opsin promoter (e.g., a red opsin promoter, a blue opsin promoter, etc.).

[0301] In some embodiments of the present disclosure, the promoter is a chicken β-actin (CB) promoter. The chicken β-actin promoter can be a short chicken β-actin promoter or a long chicken β-actin promoter. In some embodiments, the promoter (e.g., chicken β-actin promoter) comprises an enhancer sequence, such as a cytomegalovirus (CMV) enhancer sequence. The CMV enhancer sequence can be a short CMV enhancer sequence or a long CMV enhancer sequence. In some embodiments, the promoter comprises a long CMV enhancer sequence and a long chicken β-actin promoter. In some embodiments, the promoter comprises a short CMV enhancer sequence and a short chicken β-actin promoter. However, those skilled in the art will appreciate that a short CMV enhancer can be used together with a long CB promoter, and a long CMV enhancer can be used together with a short CB promoter. In some embodiments of the present disclosure, the promoter is a CBh promoter.

[0302] In some embodiments of the present disclosure, the promoter is a CBh promoter.

[0303] In some embodiments of the disclosure, the regulatory sequence comprises an HRE enhancer element.

[0304] In some embodiments of the present disclosure, the regulatory sequence comprises an NRS element and an HRE enhancer element in tandem.

[0305] The sixth aspect of the present disclosure provides a vector system, wherein the vector system comprises a polynucleotide sequence encoding the guide RNA disclosed herein and a second regulatory sequence that regulates the expression of the guide RNA; and a polynucleotide sequence encoding the RNA-guided nuclease and a first regulatory sequence that regulates the expression of the RNA-guided nuclease.

[0306] In some embodiments of the present disclosure, the vector system comprises one or more vectors.

[0307] In some embodiments of the present disclosure, the vector system comprises multiple vectors, the polynucleotide sequence encoding the guide RNA and the second regulatory sequence regulating the expression of the guide RNA are located on the second vector, and the polynucleotide sequence encoding the RNA-guided nuclease and the first regulatory sequence regulating the expression of the RNA-guided nuclease are located on the first vector.

[0308] In some embodiments of the present disclosure, the regulatory sequence is a promoter sequence. In some embodiments of the present disclosure, the regulatory sequence is an enhancer sequence. In some embodiments of the present disclosure, the regulatory sequence is a promoter and enhancer sequence.

[0309] A seventh aspect of the present disclosure provides an adeno-associated viral vector, wherein the adeno-associated viral vector comprises DNA encoding an RNA-guided nuclease and the guide RNA of the present disclosure.

[0310] An eighth aspect of the present disclosure provides a lipid nanoparticle, wherein the lipid nanoparticle comprises the guide RNA described in the present disclosure and an mRNA encoding the RNA-guided nuclease.

[0311] A ninth aspect of the present disclosure provides a lentiviral vector, wherein the lentiviral vector comprises the guide RNA disclosed herein and an mRNA encoding an RNA-guided nuclease; optionally, the lentiviral vector is pseudotyped with an envelope protein; optionally, the mRNA encoding the RNA-guided nuclease is linked to an aptamer sequence.

[0312] A tenth aspect of the present disclosure provides a ribonucleoprotein complex, wherein the ribonucleoprotein complex is formed by the guide RNA and the RNA-guided nuclease described in the present disclosure.

[0313] The eleventh aspect of the present disclosure provides a virus-like particle, wherein the virus-like particle comprises a ribonucleoprotein complex formed by the guide RNA and the RNA-guided nuclease described in the present disclosure; optionally, the RNA-guided nuclease is fused to the gag protein.

[0314] The twelfth aspect of the present disclosure provides a eukaryotic cell, which comprises the gene editing system, guide RNA, nucleic acid, vector and / or vector system described in the present disclosure; optionally, the eukaryotic cell is a mammalian cell; further optionally, the eukaryotic cell is a human cell.

[0315] In some embodiments of the present disclosure, the eukaryotic cell comprises the gene editing system described in the present disclosure.

[0316] The thirteenth aspect of the present disclosure provides a pharmaceutical composition, characterized in that the pharmaceutical composition comprises the gene editing system, guide RNA, nucleic acid, vector and / or vector system described in any one of the present disclosures.

[0317] In some embodiments of the present disclosure, the pharmaceutical composition comprises the gene editing system described in any one of the present disclosures.

[0318] In some embodiments of the present disclosure, the pharmaceutical composition comprises the guide RNA, nucleic acid, vector and / or vector system described in any one of the present disclosures.

[0319] In some embodiments of the present disclosure, the pharmaceutical composition comprises a pharmaceutically acceptable excipient.

[0320] A fourteenth aspect of the present disclosure provides use of the guide RNA, nucleic acid, vector, vector system, adeno-associated viral vector, lipid nanoparticle, lentiviral vector, ribonucleoprotein complex, virus-like particle, eukaryotic cell or pharmaceutical composition according to any one of the present disclosure in any of the following or in the preparation of a reagent for implementing any of the following schemes:

[0321] Cleave or nick one or more ADRB2 RNA molecules, activate or upregulate one or more ADRB2 RNAs, activate or inhibit translation of one or more ADRB2 RNA molecules, inactivate one or more ADRB2 RNA molecules, visualize, label or detect one or more ADRB2 RNA molecules, bind one or more ADRB2 RNA molecules, transport one or more ADRB2 RNA molecules, and mask one or more ADRB2 RNA molecules.

[0322] In some embodiments of the present disclosure, there is provided a use of the guide RNA, nucleic acid, vector, vector system, adeno-associated viral vector, lipid nanoparticle, lentiviral vector, ribonucleoprotein complex, virus-like particle, eukaryotic cell or pharmaceutical composition according to any one of the present disclosure in any of the following or in the preparation of a reagent for implementing any of the following schemes:

[0323] Cleaves ADRB2 RNA molecules, inhibits translation of ADRB2 RNA molecules, and binds to ADRB2 RNA molecules.

[0324] In some embodiments of the present disclosure, there is provided a use of the guide RNA, nucleic acid, vector, vector system, adeno-associated viral vector, lipid nanoparticle, lentiviral vector, ribonucleoprotein complex, virus-like particle, eukaryotic cell or pharmaceutical composition according to any one of the present disclosure in cleaving ADRB2 RNA molecules or preparing an agent for cleaving ADRB2 RNA molecules.

[0325] In some embodiments of the present disclosure, there is provided a use of the guide RNA, nucleic acid, vector, vector system, adeno-associated viral vector, lipid nanoparticle, lentiviral vector, ribonucleoprotein complex, virus-like particle, eukaryotic cell or pharmaceutical composition according to any one of the present disclosure in binding to ADRB2 RNA molecules or preparing an agent for binding to ADRB2 RNA molecules.

[0326] In some embodiments of the present disclosure, the ADRB2 RNA is mammalian mRNA. In some embodiments of the present disclosure, the ADRB2 RNA is mammalian mature mRNA. In some embodiments of the present disclosure, the ADRB2 RNA is human mature ADRB2 RNA.

[0327] A fifteenth aspect of the present disclosure provides a method for diagnosing, treating or preventing a disease or condition, characterized in that an effective amount of the gene editing system, guide RNA, nucleic acid, vector, vector system, adeno-associated viral vector, lipid nanoparticle, lentiviral vector, ribonucleoprotein complex, virus-like particle, eukaryotic cell and / or pharmaceutical composition according to the present disclosure is administered to a sample of a subject in need or to a subject in need.

[0328] In some embodiments of the present disclosure, a method for diagnosing, treating or preventing a disease or condition is provided, characterized in that an effective amount of the gene editing system, eukaryotic cell and / or pharmaceutical composition according to the present disclosure is administered to a sample of a subject in need or to a subject in need.

[0329] In some embodiments of the present disclosure, a method for diagnosing, treating or preventing a disease or condition is provided, characterized in that an effective amount of the gene editing system according to the present disclosure is administered to a sample of a subject in need or to a subject in need.

[0330] In some embodiments of the present disclosure, the disease or condition is a disease or condition associated with ADRB2 RNA; alternatively, the disease or condition is a disease or condition caused by abnormally high expression of ADRB2 RNA; further alternatively, the disease or condition is a disease or condition caused by abnormally high expression of ADRB2 RNA and AQP1 RNA.

[0331] In some embodiments of the present disclosure, the ADRB2 RNA is mammalian mRNA. In some embodiments of the present disclosure, the ADRB2 RNA is mammalian mature mRNA. In some embodiments of the present disclosure, the ADRB2 RNA is human mature ADRB2 RNA.

[0332] In some embodiments of the disclosure, the disease or condition is glaucoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0333] FIG1 shows a map of the C13-2-BsaI plasmid vector.

[0334] FIG2 shows a map of the RFZH-1 plasmid vector.

[0335] FIG3 shows the results of targeted editing of human hADRB2 RNA by the CasRx+gRNA system.

[0336] FIG4 shows the results of targeted editing of human hADRB2 RNA by the C13-2+gRNA system.

[0337] Figure 5 shows the results of targeted editing of mouse mARB2 RNA by the C13-2+gRNA system.

[0338] FIG6 shows the target sequences of the newly designed gRNA18-2 and gRNA18-3. DETAILED DESCRIPTION

[0339] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0340] Definition section:

[0341] As used herein, the term "gene editing system" refers to a protein, nucleic acid, or combination thereof that is capable of modifying an endogenous target nucleic acid sequence when introduced into a cell. The gene editing system includes, but is not limited to, a CRISPR-Cas system, a TALEN system, and a ZFN system.

[0342] In some embodiments, the gene editing system used in the methods described herein is a clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) nuclease system, which is an engineered nuclease system based on a bacterial system that can be used for mammalian genome engineering. Typically, the system includes a CRISPR-associated nuclease (e.g., Cas nuclease) and a guide RNA (gRNA), or their encoding nucleic acids.

[0343] As used herein, the term knockdown refers to a measurable reduction in a target RNA in a genetically modified cell compared to the level of the target RNA in a corresponding control cell that does not comprise a genetic modification that reduces expression. For example, the target RNA level in the genetically modified cell is reduced by >0%, ≥5%, ≥10%, ≥15%, ≥20%, ≥25%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, ≥80%, ≥90% or ≥95% compared to the target RNA level in the control cell. Those skilled in the art will readily understand how to use gene editing-mediated inhibition techniques to knock down a target RNA or a portion thereof based on the details described herein.

[0344] As used herein, the term inhibitor refers to selective inhibition of a target RNA, for example, reducing the expression of the target RNA, or inhibiting the translation of the target RNA. The inhibition can be artificially induced, for example, by contacting a gene editing system with the target RNA to cut the target RNA, thereby reducing the target RNA level.

[0345] As used herein, the term gene editing system guide RNA, guide RNA, guide polynucleotide, guide RNA and gRNA are used interchangeably. The term guide RNA is used to refer to a molecule that forms a complex with the RNA-guided nuclease in the gene editing system and guides the sequence-specific binding of the complex to the target sequence. The guide RNA includes a guide sequence, and the guide sequence can hybridize with the target sequence. When the nuclease guided by RNA is a Cas protein, especially a Cas13 protein, the guide RNA generally includes a directional repeat sequence connected to the guide sequence.

[0346] As used herein, the terms "guide sequence" and "targeting domain" are used interchangeably and refer to a contiguous nucleotide sequence in a gRNA that has partial or full complementarity with a target sequence in a target RNA and can hybridize to the target sequence in the target RNA through base pairing promoted by an RNA-guided nuclease. Full complementarity between the guide sequence and the target sequence described in the present invention is not required, as long as there is sufficient complementarity to cause hybridization and promote the formation of a gene editing complex.

[0347] Suitable direct repeat (DR) sequences may be present in the CRISPR locus structure of prokaryotes (such as bacteria and archaea) and obtained through experimental screening; they may also be obtained through sequence modification or optimization on this basis, non-limiting examples of which include the deletion, replacement or addition of 1, 2, 3, 4 or more complementary base pairs in the complementary double-stranded region of the secondary structure of the DR sequence, and the deletion, replacement or addition of nucleotides on the loop of the stem-loop structure of the secondary structure of the DR sequence (for example, an aptamer sequence may be inserted into the loop). The size of the direct repeat sequence is usually tens of nucleotides, and some of its fragments are reverse complementary to each other, which means that a secondary structure is formed inside the RNA molecule, such as a stem-loop structure (often called a hairpin structure), and other fragments are unstructured. When the RNA-guided nuclease is a Cas protein, the direct repeat sequence is a constant part of the gRNA molecule, which contains a strong secondary structure, which is conducive to the interaction between the Cas protein and the gRNA molecule.

[0348] The term "hybridization" or "hybridization" refers to the process in which fully or partially complementary polynucleotide chains come together to form a double-stranded structure or region under suitable hybridization conditions, including the association between the nucleic acids caused by hydrogen bonds. As used herein, the term hybridization includes situations in which double-stranded structures or regions contain one or more protrusions or mispairings. The intensity of hybridization and hybridization (that is, the intensity of association between nucleic acids) is affected by factors such as the degree of complementarity between the nucleic acids, the stringency of the conditions involved, and the Tm of the formed hybrid. Although hydrogen bonds are generally formed between adenine and thymine, adenine and uracil, or between cytosine and guanine, other non-classical base pairs can also form hydrogen bonds. It is contemplated that the modified nucleotides can form hydrogen bonds that allow or promote hybridization using non-classical approaches.

[0349] As used herein, the term target RNA refers to a polynucleotide containing a target sequence, representing a specific sequence or its reverse complement that one wishes to bind, target, or modify using a gene editing system. For example, it can be a complete mature mRNA molecule or a pre-mRNA molecule. In some cases, the target RNA can refer to ADRB2 RNA or AQP1 RNA. In some cases, the target RNA can refer to ADRB2 RNA. In some cases, the target RNA can refer to AQP1 RNA.

[0350] As used herein, the term target sequence refers to a short sequence in a target RNA molecule that is complementary (completely complementary or partially complementary) to the guide sequence of the gRNA molecule. The gene editing complex or CRISPR complex is specifically located at the target sequence by the guide sequence sequence and performs the corresponding function at or near this position. The length of the target sequence is often tens of nt (nucleotides), for example, about 10nt, about 20nt, about 30nt, about 40nt, about 50nt, about 60nt.

[0351] As used herein, the terms cleavage and cleaving refer to breaking covalent bonds (eg, covalent phosphodiester bonds) in the ribosyl phosphodiester backbone of a polynucleotide.

[0352] The ability of a guide RNA to direct a complex to bind specifically to the sequence of a target RNA can be assessed by any suitable assay. For example, components of a gene editing system sufficient to form a CRISPR complex, including the guide RNA to be tested, can be provided to a host cell having a corresponding target RNA molecule, such as by transfection of a vector encoding the components of the CRISPR complex, and then preferential cleavage within the target sequence can be assessed. Similarly, cleavage of a target RNA sequence can be assessed in a test tube by providing a target RNA, components of a CRISPR complex, including the guide RNA to be tested and a control guide RNA that is different from the test guide RNA, and comparing the ability to bind to the target RNA or the rate at which the target RNA is cut between the guide RNA to be tested and the control guide RNA. The ability of a guide RNA to direct a complex to cut a target RNA can also be assessed by the assays described above.

[0353] The term RNA-guided nuclease refers to a polypeptide that binds to a specific target RNA sequence in a sequence-specific manner, and the polypeptide is guided to the target RNA by a guide RNA that is complexed with the polypeptide and hybridized to the target sequence on the target RNA. The cleavage of the target sequence by the RNA-guided nuclease can result in chain breaks. Although RNA-guided nucleases can cut the target sequence when bound, the term RNA-guided nuclease also includes RNA-guided nucleases that are capable of binding but not cutting the target sequence. The RNA-guided nucleases described in the present disclosure include, but are not limited to, wild-type RNA-guided nucleases (e.g., C13-2, CasRx, etc.), variants thereof (e.g., mutants with complete loss of cleavage activity, mutants with partial loss of cleavage activity, mutants with increased cleavage activity, mutants with reduced off-target effects, mutants with reduced side-cutting effects), or functional fragments or fusion proteins thereof.

[0354] As used herein, the term Cas protein is a CRISPR-associated (Cas) polypeptide or protein that, when complexed or functionally combined with one or more guide RNAs, can be guided to a target sequence in a target RNA and can sometimes subsequently bind to or cleave the target RNA.

[0355] As used herein, the term "sequence identity" (identity or percent identity) is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. When a certain position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (for example, a certain position in each of the two DNA molecules is occupied by adenine, or a certain position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent sequence identity" (percent identity) between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared × 100%. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% sequence identity. Typically, comparisons are made when two sequences are aligned to produce maximum sequence identity. Such comparisons can be performed using published and commercially available alignment algorithms and programs, such as, but not limited to, ClustalΩ, MAFFT, Probcons, T-Coffee, Probalign, BLAST, which can be reasonably selected by one of ordinary skill in the art. Those skilled in the art can determine appropriate parameters for aligning sequences, including, for example, any algorithms needed to achieve better alignment or optimal comparison over the entire length of the sequences being compared, as well as any algorithms needed to achieve better alignment or optimal comparison over a portion of the sequences being compared.

[0356] As used herein, the term regulatory sequence is intended to include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory sequences include those elements that direct the continuous expression of a nucleotide sequence in many types of host cells and those elements that direct the expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can direct expression primarily in desired tissues of interest such as muscle, neurons, bones, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., neuronal cells, lymphocytes). Regulatory sequences can also direct expression in a time-dependent manner such as a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue-specific or cell-type-specific. The term regulatory sequence also encompasses enhancer elements such as WPRE, CMV enhancer, SV40 enhancer, and the intron sequence between exons 2 and 3 of rabbit β-globin. Those skilled in the art will appreciate that the design of the expression vector can depend on factors such as the selection of the host cell to be transformed, the desired expression level, and the like. The vector can be introduced into a host cell to produce the RNA-guided nuclease and / or guide RNA of the present invention.

[0357] As used herein, the term promoter has the meaning commonly recognized in the art.

[0358] As used herein, the term enhancer has the meaning commonly recognized in the art.

[0359] As used herein, when referring to a nucleotide sequence / DNA / RNA encoding a protein, RNA, or CRISPR complex, the coding sequence may be codon-optimized, for example, codon-optimized for expression in a eukaryotic cell environment, codon-optimized for expression in a mammalian cell environment, or codon-optimized for expression in a human cell environment.

[0360] As used herein, the term pharmaceutically acceptable excipient refers to a diluent, adjuvant, pharmaceutical carrier or other excipient administered together with the active ingredient. Its selection depends on the method of administration of purposes and expectation. Excipient should not be incompatible with the active ingredient, for example, producing any undesirable biological effect or interacting with any other component of the pharmaceutical composition in a harmful manner. Pharmaceutical composition can be prepared by known methods in the field of pharmaceutical preparation.

[0361] When referring to an RNA sequence, the "t" in the sequence is used interchangeably with the "u". When referring to a "guide sequence", the "t" in the sequence is used interchangeably with the "u". When referring to a "direct repeat sequence", the "t" in the sequence is used interchangeably with the "u".

[0362] guide RNA

[0363] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with an RNA-guided nuclease (also referred to as a gene editing complex) and guiding the sequence-specific binding of the complex to the target RNA.

[0364] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with an RNA-guided nuclease and directing the complex to bind to and cleave the target RNA (eg, ADRB2 RNA or AQP1 RNA).

[0365] In some embodiments of the disclosure, the complex reduces the level of the target RNA in the cell.

[0366] In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%. The reduction in the level of the target RNA can be tested using conventional methods in the art; including but not limited to the qPCR method described in the Examples, untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be used as negative controls to calculate the target RNA knockdown level of the experimental group compared to the negative control.

[0367] In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 5%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 40%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 80%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 85%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 90%.

[0368] In some embodiments of the present invention, the number of off-target genes when the complex binds to and cuts the target RNA is less than 40, less than 35, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2 or less than 1. The number of off-target genes can be determined by conventional methods in the art. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program. As a non-limiting example, the program predicts the target gene using the EMBOSS-water program in the whole genome and full cDNA sequence of the target species (Homo sapiens / Mus musculus), setting the parameters to gap_extend=0.5&gap_extend=10, using the forward and reverse strands of the gRNA guide sequence for alignment, filtering the prediction results, and obtaining predicted potential target genes (including on-target genes and off-target genes).

[0369] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein. In some embodiments, the cleavage activity of the RNA-guided nuclease is completely or partially lost.

[0370] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein.

[0371] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein, and the guide RNA comprises a guide sequence and a direct repeat sequence.

[0372] In some embodiments of the present disclosure, the Cas protein is Cas9 protein, Cas12 protein or Cas13 protein.

[0373] In some embodiments, the Cas9 protein is selected from SpCas9, SaCas9, Nme2Cas9, Nme3Cas9, CjCas9, NmCas9, and FnCas9.

[0374] In some embodiments, the Cas12 protein is selected from Cas12a protein, Cas12b protein, Cas12c protein, Cas12d protein, Cas12e protein, Cas12f protein, Cas12g protein, Cas12h protein, Cas12i protein, Cas12j protein, Cas12k protein, Cas12l protein and Cas12m protein.

[0375] In some embodiments of the present disclosure, the Cas protein is a Cas13 protein.

[0376] In some embodiments of the present disclosure, the Cas protein is Cas13a protein, Cas13b protein, Cas13c protein, Cas13d protein or Cas13j protein. In some embodiments of the present disclosure, the Cas protein is a Cas13a protein, Cas13b protein or Cas13c protein in which the catalytic center RADRB2H motif of two HEPN domains carries a mutation, and the cleavage activity of these Cas proteins is completely or partially lost. In some embodiments, the Cas protein is a CasRx protein. In some embodiments, the Cas protein is a dCasRx in which both HEPN domains carry mutations (R239A, H244A of HEPN-1 and R858A, H863A of HEPN-2).

[0377] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 700.

[0378] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:700.

[0379] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:708.

[0380] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:708.

[0381] In some embodiments of the present disclosure, the RNA-guided nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0382] In some embodiments of the disclosure, the guide sequence comprises 20-40, 20-35, 20-30, or 25-30 nucleotides.

[0383] In some embodiments of the present disclosure, the guide sequence hybridizes to the target RNA with no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 mismatch.

[0384] In some embodiments of the present disclosure, the guide sequence has 100% sequence identity with the target RNA, i.e., is fully complementary.

[0385] In some embodiments of the present disclosure, the guide sequence is located at the 3' end or 5' end of the direct repeat sequence. In some embodiments of the present disclosure, the guide sequence is located at the 3' end of the direct repeat sequence. In some embodiments of the present disclosure, the guide sequence is located at the 5' end of the direct repeat sequence.

[0386] In some embodiments of the present disclosure, the direct repeat sequence comprises the sequence shown in SEQ ID NO: 686. In some embodiments of the present disclosure, the direct repeat sequence consists of the sequence shown in SEQ ID NO: 686.

[0387] In some embodiments of the present disclosure, the guide RNA comprises an aptamer sequence.

[0388] In some embodiments of the present disclosure, the aptamer sequence is inserted into the loop of the stem-loop structure of the direct repeat sequence secondary structure of the guide RNA.

[0389] In some embodiments of the present disclosure, the guide RNA comprises modified nucleotides. The modifications include, but are not limited to, 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate or 2'-O-methyl-3'-thio PACE modifications. In some embodiments of the present disclosure, the guide RNA comprises modified nucleotides selected from deoxyribonucleotides and locked nucleic acids (LNA). In some embodiments, the guide RNA comprises at least one chemically modified nucleotide. In some embodiments, the guide RNA is a hybrid RNA-DNA guide, i.e., some RNA nucleotides in the guide RNA are replaced by DNA nucleotides. In some embodiments, the guide RNA is a hybrid RNA-LNA (locked nucleic acid) guide, i.e., some RNA nucleotides in the guide RNA are replaced by LNA nucleotides.

[0390] In some embodiments, multiple guide RNAs are part of an array (which can be part of a vector, such as a viral vector or plasmid). For example, a guide array comprising the sequence DR-spacer-DR-spacer-DR-spacer can include three unique unprocessed guide RNAs (one for each DR-spacer sequence). Once introduced into a cell or cell-free system, the array is processed into multiple individual mature guide RNAs by RNA-guided nucleases such as Cas proteins. This allows for multiplexing, such as delivering multiple guide RNAs to a cell or system to target multiple target RNAs or multiple regions within a single target RNA.

[0391] In some embodiments of the present disclosure, the target RNA is located in the nucleus and / or cytoplasm of a eukaryotic cell.

[0392] target RNA

[0393] The gene editing systems and compositions disclosed herein can be used to target one or more target RNA molecules, such as target RNA molecules present in a biological sample. In some embodiments, the target RNA is pre-mRNA or mRNA (mature mRNA).

[0394] In some embodiments of the present disclosure, the target RNA is ADRB2 RNA. In some embodiments of the present disclosure, the target RNA is human ADRB2 RNA. In some embodiments of the present disclosure, the target RNA is human ADRB2 mRNA.

[0395] In some embodiments of the present disclosure, the target RNA is AQP1 RNA. In some embodiments of the present disclosure, the target RNA is human AQP1 RNA. In some embodiments of the present disclosure, the target RNA is human AQP1 mRNA.

[0396] In some embodiments of the present disclosure, the target RNA is ADRB2 RNA or a fragment thereof.

[0397] In some embodiments of the present disclosure, the target RNA is ADRB2 mRNA or a fragment thereof.

[0398] In some embodiments of the present disclosure, the target RNA is AQP1 RNA or a fragment thereof.

[0399] In some embodiments of the present disclosure, the target RNA is AQP1 mRNA or a fragment thereof.

[0400] In some embodiments of the present disclosure, the target RNA is AQP1 pre-mRNA or a fragment thereof.

[0401] In some embodiments of the present disclosure, the gene editing system described herein can be used to reduce the expression level of ADRB2 RNA or AQP1 RNA; for example, using an RNA-guided nuclease to contact and cleave ADRB2 RNA or AQP1 RNA under the guidance of a gRNA. In some embodiments, the gene editing system described herein can be used to reduce the expression level of ADRB2 RNA or AQP1 RNA in a cell.

[0402] RNA-guided nucleases

[0403] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein.

[0404] In some embodiments of the present disclosure, the RNA-guided nuclease is selected from wild-type RNA-guided nucleases (including but not limited to CasRx, C13-2, etc.), variants thereof (including but not limited to mutants with complete loss of cleavage activity, mutants with partial loss of cleavage activity, mutants with increased cleavage activity, mutants with reduced off-target / bypass effects), or functional fragments or fusion proteins thereof.

[0405] In some embodiments of the present disclosure, the RNA-guided nuclease comprises any one or more of the following fusion domains: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0406] Exemplary fusion domains (e.g., fused heterologous protein domains) include domains that can cleave RNA (e.g., PIN endonuclease domains, NYN domains, SMR domains from SOT1, or RNase domains from staphylococcal nuclease), domains that can affect RNA stability (e.g., tristetraprolin (TTP) or domains from UPF1, EXOSC5, and STAU1), domains that can edit nucleotides or ribonucleotides (e.g., cytidine deaminases, PPR proteins, adenosine deaminases, ADAR family proteins, or APOBEC family proteins), domains that can activate translation (e.g., eIF4E and other translation initiation factors, yeast poly(A) binding protein, or domains of GLD2), domains that can inhibit translation (e.g., Pumilio or FBF). These proteins may be PUF proteins, deadenylases, CAF1, Argonaute proteins), domains that can methylate RNA (e.g., domains from m6A methyltransferase factors such as METTL14, METTL3, or WTAP), domains that can demethylate RNA (e.g., human alkylation repair homolog 5), domains that can affect splicing (e.g., the RS-rich domain of SRSF1, the Gly-rich domain of hnRNP A1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), domains that can enable affinity purification or immunoprecipitation (e.g., FLAG, HA, biotin, or HALO tags), and domains that can enable proximity-based protein labeling and recognition (e.g., biotin ligases such as BirA or peroxidases such as APEX2 to biotinylate target DNA-interacting proteins).

[0407] In some embodiments, the fusion domain comprises an adenosine deaminase domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an adenosine deaminase domain to guide the A-to-I deaminase activity of RNA transcripts in mammalian cells. For example, an adenosine deaminase domain engineered for targeted A-to-I RNA editing based on ADAR2 is fused. In other embodiments, the adenosine deaminase domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to a guide RNA, thereby allowing the adenosine deaminase domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0408] In some embodiments, the fusion domain comprises a cytosine deaminase domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a cytosine deaminase domain to guide the C-to-U deaminase activity of RNA transcripts in mammalian cells. For example, a cytosine deaminase domain for targeting C-to-U RNA editing evolved using ADAR2 is used. In other embodiments, the cytosine deaminase domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to a guide RNA, thereby allowing the cytosine deaminase domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0409] In some embodiments, the fusion domain comprises a splicing factor domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a splicing factor domain to guide the alternative splicing of the target RNA in a mammalian cell. Non-limiting examples of splicing factor domains include the RS-rich domain of SRSF1, the Gly-rich domain of hnRNPA1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1. In other embodiments, the splicing factor domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the splicing factor domain to be non-covalently linked to the Cas13 protein compounded with the guide RNA.

[0410] In some embodiments, the fusion domain includes a translation activation domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a translation activation domain to activate or increase the expression of the target RNA. Non-limiting examples of translation activation domains include eIF4E and other translation initiation factors, yeast poly (A) binding protein or the domain of GLD2. In other embodiments, the translation activation domain is covalently linked or fused to a linker protein that can bind to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the translation activation domain to be non-covalently linked to the Cas13 protein compounded with the guide RNA.

[0411] In some embodiments, the fusion domain comprises a translation inhibition domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a translation inhibition domain to inhibit or reduce the expression of the target RNA. Non-limiting examples of translation inhibition domains include Pumilio or FBF PUF proteins, deadenylase, CAF1, Argonaute proteins. In other embodiments, the translation inhibition domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the translation inhibition domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0412] In some embodiments, the fusion domain comprises an RNA methylation domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an RNA methylation domain for methylation of the target RNA. Non-limiting examples of RNA methylation domains include m6A domains, such as METTL14, METTL3, or WTAP. In other embodiments, the RNA methylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the RNA methylation domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0413] In some embodiments, the fusion domain comprises an RNA demethylation domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an RNA demethylation domain for demethylation of the target RNA. Non-limiting examples of RNA demethylation domains include human alkylation repair homolog 5 or ALKBH5. In other embodiments, the RNA demethylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the RNA demethylation domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0414] In some embodiments, the fusion domain comprises a ribonuclease domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a ribonuclease domain to cleave the target RNA. Non-limiting examples of ribonuclease domains include a PIN endonuclease domain, a NYN domain, an SMR domain from SOT1, or an RNase domain from Staphylococcus nuclease.

[0415] In some embodiments, the fusion domain includes an affinity tag or a reporter domain. In some embodiments, Cas13 protein is covalently linked to or fused to a reporter domain, such as a fluorescent protein. Non-limiting examples of reporter domains include GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP. In some embodiments, Cas13 protein is covalently linked to or fused to an affinity tag such as a purification tag. Non-limiting examples of affinity tags include HA-tags, His-tags (e.g., 6-His), Myc-tags, E-tags, S-tags, calmodulin tags, FLAG-tags, GST-tags, MBP-tags, Halo tags, or biotin.

[0416] In some embodiments of the present disclosure, the fusion domain is located at the N-terminus, C-terminus, or both the N-terminus and the C-terminus of the RNA-guided nuclease. In some embodiments of the present disclosure, the N-terminus, C-terminus, or both the N-terminus and the C-terminus of the RNA-guided nuclease are fused with 0, 1, 2, 3, 4 or more fusion domains, respectively.

[0417] In some embodiments of the present disclosure, the RNA-guided nuclease is covalently linked to the fusion domain with or without a linker sequence; that is, the RNA-guided nuclease is directly covalently linked to the fusion domain (without a linker sequence) or covalently linked via a linker sequence. Typically, the linker sequence consists of 1-100, 1-50, 1-30, 1-20, 1-10, or 1-5 amino acids.

[0418] In some embodiments of the present disclosure, the RNA-guided nuclease comprises a subcellular localization signal.

[0419] In some embodiments of the present disclosure, the RNA-guided nuclease comprises a subcellular localization signal and a deaminase domain.

[0420] In some embodiments of the present disclosure, the subcellular localization signal is selected from a nuclear localization signal and a nuclear export signal.

[0421] In some embodiments, the RNA-guided nuclease is fused to at least one subcellular localization signal. Exemplary subcellular localization signals include organelle localization signals, such as a nuclear localization signal (NLS), a nuclear export signal (NES), or a mitochondrial localization signal.

[0422] In some embodiments, the RNA-guided nuclease is fused to at least one heterologous NLS. In some embodiments, the RNA-guided nuclease is fused to at least two NLSs. In some embodiments, the RNA-guided nuclease is fused to at least three NLSs. In some embodiments, the RNA-guided nuclease is fused to at least one N-terminal NLS and at least one C-terminal NLS. In some embodiments, the RNA-guided nuclease is fused to at least two C-terminal NLSs. In some embodiments, the RNA-guided nuclease is fused to at least two N-terminal NLSs.

[0423] In some embodiments, the RNA-guided nuclease is fused to a heterologous NES. In some embodiments, the RNA-guided nuclease is fused to at least two NESs. In some embodiments, the RNA-guided nuclease is fused to at least three NESs. In some embodiments, the RNA-guided nuclease is fused to at least one N-terminal NES and at least one C-terminal NES. In some embodiments, the RNA-guided nuclease is fused to at least two C-terminal NESs. In some embodiments, the RNA-guided nuclease is fused to at least two N-terminal NESs.

[0424] In some embodiments, the NES is independently selected from an adenovirus type 5 E1B NES, an HIV Rev NES, a MAPK NES, or a PTK2 NES.

[0425] In some embodiments, the RNA-guided nuclease is fused to an NLS and an NES, with a cleavable linker present between the NLS and the NES. In some embodiments, the NES promotes production of delivery particles (e.g., virus-like particles) comprising the RNA-guided nuclease in a production cell line. In some embodiments, cleavage of the linker in a target cell can expose the NLS and promote nuclear localization of the RNA-guided nuclease in the target cell.

[0426] In some embodiments of the present disclosure, the RNA-guided nuclease is covalently linked to the fusion domain with or without a linker sequence; that is, the RNA-guided nuclease is directly covalently linked to the fusion domain (without a linker sequence) or covalently linked via a linker sequence. Typically, the linker sequence consists of 1-100, 1-50, 1-30, 1-20, 1-10, or 1-5 amino acids.

[0427] Cas proteins

[0428] In some embodiments of the present disclosure, the Cas protein is Cas9 protein, Cas12 protein or Cas13 protein. In some embodiments, the Cas protein is Cas12a protein, Cas12b protein, Cas12c protein, Cas12d protein, Cas12e protein, Cas12f protein, Cas12g protein, Cas12h protein, Cas12i protein, Cas12j protein, Cas12k protein.

[0429] In some embodiments of the present disclosure, the Cas9 protein is selected from SpCas9, SaCas9, NmeCas9, SauriCas9, and CjCas9, and the Cas12 protein is selected from AsCpf1, LbCas12a, AkCas12b, AacCas12b, PlmCasX, DpbCasX, Cas12i1, Cas12i2, Cas12i3,

[0430] In some embodiments of the present disclosure, the Cas protein is a Cas13 protein. In some embodiments of the present disclosure, the Cas13 protein is optionally selected from LsCas13a, LwaCas13a, PspCas13b, BzCas13b, PbCas13b, Cas13X.1, Cas13X.2, Cas13Y.1, Cas13Y.2, Cas13Y.3, CasRx, C13-2, EsCas13d, and RspCas13d.

[0431] In some embodiments of the present disclosure, the Cas protein is Cas13a protein, Cas13b protein, Cas13c protein, Cas13d protein or Cas13j protein. In some embodiments of the present disclosure, the Cas protein is a Cas13a protein, a Cas13b protein or a Cas13c protein in which two HEPN domains carry mutations, and the cleavage activity of these Cas proteins is completely or partially lost. In some embodiments, the Cas protein is a CasRx protein. In some embodiments, the Cas protein is a dCasRx in which two HEPN domains carry mutations (R239A, H244A of HEPN-1 and R858A, H863A of HEPN-2). In some embodiments, the Cas13b protein includes Cas13X protein and Cas13Y protein. The Cas13X protein includes but is not limited to Cas13X.1 or its variants, Cas13X.2 or its variants; the Cas13Y protein includes but is not limited to Cas13Y.1 or its variants, Cas13Y.2 or its variants, Cas13Y.3 or its variants, Cas13Y.4 or its variants, Cas13Y.5 or its variants, Cas13Y.6 or its variants.

[0432] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 700.

[0433] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:700.

[0434] In some embodiments of the present disclosure, the Cas13 protein comprises a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:708.

[0435] In some embodiments of the present disclosure, the Cas13 protein comprises the sequence shown in SEQ ID NO:708.

[0436] In some embodiments of the present disclosure, the Cas protein comprises any one or more of the following fusion domains: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0437] In some embodiments of the present disclosure, the Cas protein comprises a subcellular localization signal.

[0438] In some embodiments of the present disclosure, the Cas protein comprises a subcellular localization signal and a deaminase domain.

[0439] In some embodiments of the present disclosure, the subcellular localization signal is selected from a nuclear localization signal and a nuclear export signal.

[0440] In some embodiments of the present disclosure, the Cas protein is covalently linked to the fusion domain with or without a linker sequence; that is, the Cas protein is directly covalently linked to the fusion domain (without a linker sequence) or covalently linked via a linker sequence. Typically, the linker sequence consists of 1-100, 1-50, 1-30, 1-20, 1-10, or 1-5 amino acids.

[0441] Nucleotide sequence encoding guide RNA or RNA-guided nuclease

[0442] In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is a plasmid. In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is part of a viral vector genome, such as the DNA genome of an AAV vector flanked by ITRs. In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is an mRNA.

[0443] In some embodiments of the present disclosure, the nucleotide sequence encoding the guide RNA or RNA-guided nuclease is codon-optimized.

[0444] In some embodiments of the present disclosure, the nucleotide sequence encoding the guide RNA is DNA. In some embodiments, the sequence of the DNA is codon optimized.

[0445] In some embodiments of the present disclosure, the nucleotide sequence encoding the RNA-guided nuclease is DNA or mRNA. In some embodiments, the sequence of the DNA is codon-optimized. In some embodiments, the sequence of the mRNA is codon-optimized.

[0446] In some embodiments of the present disclosure, codon optimization is performed for expression in a desired cell type. In some embodiments, codon optimization is performed for expression in a eukaryotic cell environment. In some embodiments, codon optimization is performed for expression in a mammalian cell environment. In some embodiments, codon optimization is performed for expression in a human cell environment.

[0447] Generally, codon optimization refers to the modification of nucleic acid sequences to enhance expression in the host cell of interest by replacing at least one codon (e.g., about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of the original sequence with codons that are more frequently used in the genes of the host cell and simultaneously maintaining the original amino acid sequence. Calculation programs or algorithms for codon optimization are also available, such as those available using the following tools or algorithms: ExpOptimizer, Codon OptimWiz, NGTM Codon, Codon optimization, Synthetic Gene Designer, and DNAWorks, etc.

[0448] carrier

[0449] Vectors can comprise any type of nucleotides, including but not limited to DNA and RNA, which can be single-stranded or double-stranded, can be partially obtained from natural sources, and can comprise natural, non-natural or altered nucleotides. Suitable vectors include those designed for expression, such as plasmids and viruses.

[0450] In some embodiments, recombinant vectors contain regulatory sequences, such as transcriptional and translational start and stop codons, that are specific for the type of host cell into which the vector is to be introduced (eg, bacteria, fungi, plants, or animals, as appropriate).

[0451] In some embodiments, the recombinant vector optionally includes a gene carrier element (nucleic acid), such as a selectable marker region, a lactose operon, a CMV promoter, a CAG promoter, a tac promoter, a T7 RNA polymerase promoter, an SP6 RNA polymerase promoter, an SV40 promoter, an IRES sequence, a WPRE element, an ITR sequence, a FLAG tag coding region, a c-myc tag coding region, a polyHis tag coding region, an HA tag coding region, an MBP tag coding region, a GST tag coding region, a ployA coding region, an SV40 polyadenylation signal, an SV40 replication origin, a Col E1 replication origin, a loxP site, or a Cre recombinase coding region.

[0452] Regulatory sequences

[0453] In some embodiments of the present disclosure, the regulatory sequence comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof.

[0454] promoter

[0455] In some embodiments of the present disclosure, the vector comprises a pol III promoter (e.g., U6 and H1 promoters), a pol II promoter (e.g., retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), cytomegalovirus (CMV) promoter (optionally with CMV enhancer), SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter, or EF1α promoter), or a pol III promoter and a pol II promoter.

[0456] In some embodiments of the present disclosure, the promoter is a constitutive promoter, which is continuously active and not regulated by external signals or molecules. Suitable constitutive promoters include, but are not limited to, CMV, RSV, SV40, EF1α, CAG, and β-actin promoters. In some embodiments, the promoter is an inducible promoter regulated by external signals or molecules (e.g., transcription factors).

[0457] In some embodiments of the present disclosure, the promoter is a tissue-specific promoter, which can be used to drive the tissue-specific expression of Cas13 protein. Suitable muscle-specific promoters include but are not limited to CK8, MHCK7, myoglobin promoter (Mb), desmin (Desmin) promoter, muscle creatine kinase promoter (MCK) and variants thereof, and SPc5-12 synthetic promoters. Suitable immune cell-specific promoters include but are not limited to B29 promoter (B cell), CD14 promoter (monocyte), CD43 promoter (leukocyte and platelet), CD68 (macrophage) and SV40 / CD43 promoter (leukocyte and platelet). Suitable blood cell-specific promoters include but are not limited to CD43 promoter (leukocyte and platelet), CD45 promoter (hematopoietic cell), INF-β (hematopoietic cell), WASP promoter (hematopoietic cell), SV40 / CD43 promoter (leukocyte and platelet), and SV40 / CD45 promoter (hematopoietic cell). Suitable pancreas-specific promoters include but are not limited to elastase-1 promoter. Suitable endothelial cell-specific promoters include, but are not limited to, the Fit-1 promoter and the ICAM-2 promoter. Suitable neuronal tissue / cell-specific promoters include, but are not limited to, the GFAP promoter (astroglial cells), the SYN1 promoter (neurons), and the NSE / RU5' promoter (mature neurons). Neuronal tissue / cell-specific promoters can be the GFAP promoter and the SYN1 promoter. Suitable kidney-specific promoters include, but are not limited to, the NphsI promoter (podocytes). Suitable bone-specific promoters include, but are not limited to, the OG-2 promoter (osteoblasts, odontoblasts). Suitable lung-specific promoters include, but are not limited to, the SP-B promoter (lungs). Suitable liver-specific promoters include, but are not limited to, the SV40 / Alb promoter. Suitable heart-specific promoters include, but are not limited to, α-MHC.

[0458] In some embodiments of the present disclosure, the promoter is an eye-specific promoter.

[0459] In some embodiments of the present disclosure, the eye-specific promoter is selected from the group consisting of: a retinoschisis protein promoter, a K12 promoter, a rhodopsin promoter, a rod-specific promoter, a cone-specific promoter, a rhodopsin kinase promoter, a GRK1 promoter, an interphotoreceptor retinoid-binding protein proximal (IRBP) promoter, and an opsin promoter (e.g., a red opsin promoter, a blue opsin promoter, etc.).

[0460] In some embodiments of the present disclosure, the promoter is a chicken β-actin (CB) promoter. The chicken β-actin promoter can be a short chicken β-actin promoter or a long chicken β-actin promoter. In some embodiments, the promoter (e.g., chicken β-actin promoter) comprises an enhancer sequence, such as a cytomegalovirus (CMV) enhancer sequence. The CMV enhancer sequence can be a short CMV enhancer sequence or a long CMV enhancer sequence. In some embodiments, the promoter comprises a long CMV enhancer sequence and a long chicken β-actin promoter. In some embodiments, the promoter comprises a short CMV enhancer sequence and a short chicken β-actin promoter. However, those skilled in the art will appreciate that a short CMV enhancer can be used together with a long CB promoter, and a long CMV enhancer can be used together with a short CB promoter. In some embodiments of the present disclosure, the promoter is a CBh promoter.

[0461] enhancer

[0462] In some embodiments of the present disclosure, the enhancer is selected from the group consisting of WPRE, CMV enhancer, SV40 enhancer, and an intronic sequence between exons 2 and 3 of rabbit β-globin.

[0463] In some embodiments of the present disclosure, the enhancer is located upstream of the promoter element; however, it can also be located downstream or within the coding sequence regulated by the promoter and maintain function. Therefore, the enhancer or a portion thereof can be present in the RNA sequence transcribed from the coding sequence.

[0464] In some embodiments of the present disclosure, the enhancer may be located within 100, 200, 300, 400, 500 or more base pairs upstream or downstream of the coding sequence regulated by the promoter.

[0465] In some embodiments of the disclosure, an enhancer increases expression of a coding sequence above that provided by a promoter.

[0466] Adeno-associated virus vector (AAV vector)

[0467] In some embodiments of the present disclosure, the AAV vector comprises a ssDNA genome comprising coding sequences for an RNA-guided nuclease and a guide RNA flanked by ITRs.

[0468] In some embodiments of the present disclosure, the guide RNA or gene editing system described herein is packaged in an AAV vector, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV PHP.B, AAV PHP.B2, AAV PHP.B3, AAV PHP.A, AAV PHP.eB, AAV PHP.eS, AAV2.7m8, AAV8.7m8, AAV ShH10, AAVrh10, or AAVrh74. In some embodiments, the gene editing system described herein is packaged in an AAV vector comprising an engineered capsid with tissue tropism, such as an engineered neural tissue tropism capsid.

[0469] lipid nanoparticles

[0470] In some embodiments of the present disclosure, in addition to RNA payload (mRNA and guide RNA encoding the nuclease guided by RNA), lipid nanoparticles (LNPs) also include four components: cations or ionizable lipids, cholesterol, helper lipids, and PEG-lipids. In some embodiments, the cations or ionizable lipids include cKK-E12, C12-200, ALC-0315, DLin-MC3-DMA, DLin-KC2-DMA, FTT5, Moderna SM-102, and Intellia LP01. In some embodiments, the PEG-lipid includes PEG-2000-C-DMG, PEG-2000-DMG, or ALC-0159. In some embodiments, the helper lipid includes DSPC.

[0471] Lentiviral vectors

[0472] In some embodiments of the present disclosure, the lentiviral vector is pseudotyped with a homologous or heterologous envelope protein, such as VSV-G. In some embodiments, the mRNA encoding the RNA-guided nuclease is linked to an aptamer sequence.

[0473] Aptamer / aptamer sequence

[0474] In some embodiments, the guide polynucleotide further comprises an aptamer sequence. In some embodiments, the aptamer sequence is inserted into a loop of the guide polynucleotide. In some embodiments, the aptamer sequence is attached to the end of the guide polynucleotide.

[0475] In some embodiments, the aptamer sequence comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a Qβ aptamer sequence.

[0476] Adaptor protein

[0477] In some embodiments, the gene editing system further comprises a fusion protein comprising an adaptor protein and a fusion domain, or a nucleic acid encoding the fusion protein, wherein the adaptor protein is capable of binding to an aptamer sequence.

[0478] In some embodiments, the linker protein comprises an MS2 phage coat protein (MCP), a PP7 phage coat protein (PCP), or a Qβ phage coat protein (QCP). In some embodiments, the fusion domain comprises a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, or an affinity or reporter tag or domain.

[0479] RNP complex (ribonucleoprotein complex)

[0480] In some embodiments of the present disclosure, the RNP complex (ribonucleoprotein complex) can be delivered to eukaryotic cells, mammalian cells or human cells by microinjection or electroporation. In some embodiments, the ribonucleoprotein complex can be packaged in virus-like particles and delivered to mammals or human subjects in vivo.

[0481] virus-like particles

[0482] In some embodiments of the present disclosure, engineered virus-like particles (VLPs) are pseudotyped with homologous or heterologous envelope proteins such as VSV-G. In some embodiments, the RNA-guided nuclease is fused to a gag protein (e.g., MLVgag) via a cleavable linker, wherein the cleavage of the linker in the target cell exposes an NLS between the linker and the RNA-guided nuclease. In some embodiments, the fusion protein comprises (e.g., from 5' to 3') a gag protein (e.g., MLVgag), one or more NESs, a cleavable linker, one or more NLSs, and an RNA-guided nuclease. In some embodiments, the RNA-guided nuclease is fused to a first dimerization domain capable of dimerizing or heterodimerizing with a second dimerization domain fused to a membrane protein, wherein the presence of a ligand promotes the dimerization and enriches the RNA-guided nuclease or fusion protein into the VLP.

[0483] eukaryotic cells

[0484] In some embodiments of the present disclosure, the eukaryotic cell is a mammalian cell or a human cell. In some embodiments, the eukaryotic cell is a primary eukaryotic cell, a stem cell, a tumor / cancer cell, a circulating tumor cell (CTC), a blood cell (for example, a T cell, a B cell, a NK cell, a Tregs cell, etc.), a hematopoietic stem cell, a specialized immune cell (such as a tumor infiltrating lymphocyte or a tumor suppressor lymphocyte), a stromal cell (such as a cancer-associated fibroblast, etc.) in a tumor microenvironment. In some embodiments, the cell is a brain or neuronal cell (for example, a neuron, astrocyte, microglia, retinal ganglion cell, a rod / cone cell, etc.) of a central or peripheral nervous system.

[0485] Disease or condition

[0486] In some embodiments of the present disclosure, the disease or disorder is a disease or disorder caused by abnormally high expression of target RNA (eg, ADRB2 RNA and / or AQP1 RNA).

[0487] In some embodiments, the pharmaceutical composition is delivered to a human subject in vivo. The pharmaceutical composition can be delivered by any effective route, and a therapeutically effective amount of the pharmaceutical composition can be delivered to a subject in need thereof. Exemplary routes of administration include, but are not limited to, intravenous infusion, intravenous injection, intraperitoneal injection, intramuscular injection, intratumoral injection, subcutaneous injection, intradermal injection, intraventricular injection, intravascular injection, intracerebellar injection, intraocular injection, subretinal injection, intravitreal injection, intracameral injection, intratympanic injection, intranasal administration, and inhalation.

[0488] In some embodiments of the present disclosure, a therapeutically effective amount of the gene editing system or pharmaceutical composition described herein is delivered to a subject in need using a suitable delivery method, which can reduce intraocular pressure and thereby treat diseases such as glaucoma.

[0489] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0490] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0491] Example

[0492] Example 1. gRNA design and vector construction

[0493] In this example, to verify the effect of targeting ADRB2, the applicant's recently discovered highly active Cas13 protein, C13-2 (also known as CasRfg.4), whose amino acid sequence is shown in SEQ ID NO: 700, was used.

[0494] SEQ ID NO: 700 (amino acid sequence of C13-2 protein):

[0495] A gRNA targeting human ADRB2 mRNA (SEQ ID NO: 684, NCBI No. NM_000024.6) was designed. The nucleic acid sequence of the gRNA includes a guide sequence and a DR sequence. The guide sequence is reverse complementary to the target sequence on the ADRB2 RNA molecule and has a length of 20-30 nt, as shown in SEQ ID NO: 1-683.

[0496] Among them, gRNA1-gRNA11 targets human and mouse homologous sequences, and some gRNAs are also used to target mouse ADRB2 RNA (NCBI No. NM_007420.3).

[0497] C13-2-ADRB2-gRNA vector construction

[0498] The C13-2-BsaI plasmid vector (SEQ ID NO: 685) was prepared by conventional methods, and the map is shown in Figure 1. This plasmid was used to express C13-2 and gRNA (5'-DR-guide-3').

[0499] The direct repeat sequence (DR sequence) of C13-2 gRNA is shown in SEQ ID NO: 686.

[0500] The C13-2-BsaI plasmid was linearized by enzyme digestion with BsaI enzyme, and the digestion product was electrophoresed on agarose gel and the gel was cut to recover the digestion product.

[0501] Oligo DNA corresponding to the guide sequence was synthesized separately. According to the selection of BsaI restriction site, the sense chain was the 5' end of the guide sequence plus AGAC, and the antisense chain was the 5' end of the reverse complementary sequence of the guide sequence plus AAAA.

[0502] The sense and antisense strands of the oligo DNA corresponding to the guide sequence were mixed, incubated at 95°C, and then placed on ice for cooling and annealing to form double-stranded DNA with sticky ends.

[0503] The annealed product and the enzyme linearized product were ligated using T4 ligase, and the ligated product was transformed into Escherichia coli competent cells Stbl3 using the heat shock method. After transformation, LB liquid culture medium without antibiotics was added to the centrifuge tube and placed in a constant temperature shaker at 37°C for 1 hour to allow the bacteria to recover.

[0504] Spread the revived Stbl3 bacteria onto ampicillin-resistant LB agar plates and incubate them upside down in a constant temperature incubator at 37°C. Pick individual colonies from the plates, screen for positive clones, and inoculate them into ampicillin-containing LB liquid medium and culture at 37°C with shaking for 16 hours.

[0505] After plasmid extraction and plasmid concentration determination, a portion of the plasmid was taken for Sanger sequencing, and the correctly sequenced plasmid was stored at -20°C for future use.

[0506] The constructed vector expressing C13-2 and the sequence of gRNAn targeting ADRB2 RNA was named C13-2-ADRB2-gRNAn (n is a numerical sequence).

[0507] CasRx-ADRB2-gRNA vector construction

[0508] The RFZH-1 plasmid vector (SEQ ID NO: 687) was prepared by conventional methods, and the map is shown in Figure 2. This plasmid is used to express CasRx and gRNA. The CasRx is a fusion protein comprising the sequence shown in SEQ ID NO: 708 (CasRx portion) and NLS and HA tags fused at both ends.

[0509] The RFZH-1 plasmid was linearized using BpiI enzyme digestion, and the digestion products were electrophoresed on agarose gel and recovered by gel excision.

[0510] Oligo DNA corresponding to the guide sequence was synthesized separately. According to the selection of BpiI restriction site, the sense chain was the 5' end of the guide sequence plus AAAC, and the antisense chain was the 5' end of the reverse complementary sequence of the guide sequence plus CTTG.

[0511] The sense and antisense strands of the oligo DNA corresponding to the guide sequence were mixed, incubated at 95°C, and then placed on ice for cooling and annealing to form double-stranded DNA with sticky ends.

[0512] The annealed product and the enzyme linearized product were ligated using T4 ligase, and the ligated product was transformed into Escherichia coli competent cells Stbl3 using the heat shock method. After transformation, LB liquid culture medium without antibiotics was added to the centrifuge tube and placed in a constant temperature shaker at 37°C for 1 hour to allow the bacteria to recover.

[0513] Spread the revived Stbl3 bacteria onto ampicillin-resistant LB agar plates and incubate them upside down in a constant temperature incubator at 37°C. Pick individual colonies from the plates, screen for positive clones, and inoculate them into ampicillin-containing LB liquid medium and culture at 37°C with shaking for 16 hours.

[0514] After plasmid extraction and plasmid concentration determination, a portion of the plasmid was taken for Sanger sequencing, and the correctly sequenced plasmid was stored at -20°C for future use.

[0515] The constructed vector expressing CasRx and gRNAn targeting ADRB2 RNA was named CasRx-ADRB2-gRNAn (n is a numerical number).

[0516] C13-2-AQP1-gRNA4-ADRB2-gRNA10 dual-target vector

[0517] A gRNA targeting human AQP1 mRNA (SEQ ID NO: 703, NCBI accession number NM_198098.4) was designed. The gRNA's nucleic acid sequence includes a guide sequence and a DR sequence, which are reverse complementary to the target sequence on the AQP1 RNA molecule. Experimental screening identified gRNA 4 targeting AQP1 with high editing efficiency, containing the guide sequence agggcagaaccgatgctgatgaagac (SEQ ID NO: 704).

[0518] The C13-2-AQP1-gRNA4-ADRB2-gRNA10 vector was constructed using conventional methods, and its sequence is shown in SEQ ID NO: 701. This vector has a similar architecture to the C13-2-ADRB2-gRNA vector described above, except that it contains expression cassettes for gRNA4 targeting AQP1 RNA and gRNA10 targeting ADRB2 RNA, with expression of each gRNA driven by its corresponding U6 promoter.

[0519] Example 2: Plasmid transfection and Q-PCR detection

[0520] Plasmid transfection and Q-PCR of 293T cells

[0521] The plasmid Lv-CMV-hADRB2-T2A-GFP (SEQ ID NO: 688) overexpressing human hADRB2 was constructed.

[0522] Add 500 ng of the gRNA plasmid from Example 1 and 20 ng of the human hADRB2 overexpressing plasmid to 50 μl of Opti-MEM I Reduced Serum Medium and mix gently. Add 1 μl of Lipofectamine 2000 to 50 μl of Opti-MEM I Reduced Serum Medium and mix gently. Gently mix the two dilutions and let them stand at room temperature for 20 minutes.

[0523] The mixture was added to a 24-well plate in which 293T cells had been plated 24 hours in advance (cell confluence was about 30%-50%).

[0524] The negative control (NC) group was transfected with C13-2-Luc plasmid and Lv-CMV-hADRB2-T2A-GFP plasmid, or CasRx-Luc (SEQ ID NO: 689, expressing CasRx and gRNA targeting luciferase) and Lv-CMV-hADRB2-T2A-GFP plasmid.

[0525] The difference between the control plasmid C13-2-Luc and the C13-2-ADRB2-gRNA10 plasmid sequence is only that the guide sequence is replaced with a guide sequence targeting luciferase luciferase (SEQ ID NO: 699). The C13-2-Luc plasmid can express C13-2 and gRNA targeting luciferase (gRNA-Luc).

[0526] 72 hours after plasmid transfection, total RNA was extracted from cells using an RNA extraction kit, and gDNA was digested and reverse transcribed using the Evo M-MLV RT Kit with gDNA Clean for qPCR reverse transcription kit to obtain the corresponding cDNA. The Green Premix Pro Taq HS qPCR Kit was used to measure the levels of human hADRB2 RNA after targeted editing in each group, using GAPDH as an internal control. Each primer pair was used in triplicate for each sample. Q-PCR primers are listed in Table 1.

[0527] Table 1. Primers used for Q-PCR in targeted editing of human ADRB2 RNA

[0528] Plasmid transfection and Q-PCR in N2a cells

[0529] The plasmid Lv-CMV-mADRB2-T2A-GFP (SEQ ID NO: 694) overexpressing mouse mADRB2 was constructed.

[0530] To 50 μl of Opti-MEM I Reduced Serum Medium, add 500 ng of the gRNA plasmid from Example 1 and 20 ng of the plasmid overexpressing murine mARB2 and mix gently. To 50 μl of Opti-MEM I Reduced Serum Medium, add 1 μl of Lipofectamine 2000 and mix gently. Gently mix the two dilutions and let them stand at room temperature for 20 minutes.

[0531] The mixture was added to a 24-well plate in which N2a cells had been seeded 24 hours in advance (cell confluence was about 30%).

[0532] The negative control (NC) group was transfected with the aforementioned C13-2-Luc plasmid and Lv-CMV-mADRB2-T2A-GFP plasmid, or CasRx-Luc and Lv-CMV-mADRB2-T2A-GFP plasmid.

[0533] 72 hours after plasmid transfection, total RNA was extracted from cells using an RNA extraction kit, and gDNA was digested and reverse transcribed using the Evo M-MLV RT Kit with gDNA Clean for qPCR reverse transcription kit to obtain the corresponding cDNA. The Green Premix Pro Taq HS qPCR Kit was used to measure the RNA levels of mouse mARB2 after targeted editing in each group, using β-actin as an internal control. Q-PCR was performed in triplicate for each primer pair per sample. Q-PCR primers are listed in Table 2.

[0534] Table 2. Primers used for Q-PCR targeting of mouse ADRB2 RNA

[0535] Knockdown results

[0536] The results were calculated using the 2^-ΔΔCt method and the average value of three tests was used.

[0537] The test results of knocking down ADRB2 RNA using the Cas13 system are shown in Tables 3-5 and Figures 3-5. The combined editing of the gRNA designed by the inventors and Cas13 can significantly reduce the expression levels of human and mouse ADRB2 RNA.

[0538] In human 293T cells, when gRNA was combined with CasRx, gRNA10 and 18 had the strongest knockdown effect on hADRB2 RNA.

[0539] In human 293T cells, when gRNA was combined with C13-2, gRNAs 8, 10, 17, and 18 had the strongest knockdown effect on hADRB2 RNA.

[0540] In mouse N2a cells, when gRNA was combined with C13-2, gRNA7 and 10 had the strongest knockdown effect on mARB2 RNA.

[0541] Table 3. Results of CasRx system editing of human hADRB2 RNA

[0542] Table 4. Results of editing human hADRB2 RNA using the C13-2 system

[0543] Table 5. Results of editing mouse mARB2 RNA using the C13-2 system

[0544] Simultaneous knockdown of AQP1 and ADRB2 expression at the cellular level

[0545] The plasmid Lv-CMV-hAQP1-T2A-GFP (SEQ ID NO: 702) overexpressing human hAQP1 and the plasmid Lv-CMV-hADRB2-T2A-GFP (SEQ ID NO: 688) overexpressing human hADRB2 were constructed.

[0546] To 50 μl of Opti-MEM I Reduced Serum Medium, add 500 ng of the dual-target vector plasmid from Example 1, 20 ng of the plasmid overexpressing human hAQP1, and 20 ng of the plasmid overexpressing human hADRB2 and mix gently. To 50 μl of Opti-MEM I Reduced Serum Medium, add 1 μl of Lipofectamine 2000 and mix gently. Gently mix both dilutions and let them stand at room temperature for 20 minutes.

[0547] The mixture was added to a 24-well plate in which 293T cells had been plated 24 hours in advance (cell confluence was about 30%-50%).

[0548] The negative control group was transfected with the aforementioned C13-2-Luc plasmid, a plasmid overexpressing human hAQP1, and a plasmid overexpressing human hADRB2. The control plasmid C13-2-Luc differed from the C13-2-ADRB2-gRNA10 plasmid sequence of Example 1 only in that the guide sequence was replaced with a guide sequence targeting luciferase (SEQ ID NO: 699), which can express C13-2 and a gRNA targeting luciferase (gRNA-Luc).

[0549] 72 hours after plasmid transfection, total RNA was extracted from cells using an RNA extraction kit, and gDNA was digested and reverse transcribed using the Evo M-MLV RT Kit with gDNA Clean for qPCR reverse transcription kit to obtain the corresponding cDNA. The Green Premix Pro Taq HS qPCR Kit was used to measure the levels of human AQP1 and hADRB2 RNA after targeted editing in each group, using GAPDH as an internal control. Each primer pair was used in triplicate for each sample. Q-PCR primers are listed in Table 6.

[0550] Table 6. Primers used for Q-PCR targeting human hAQP1 and hADRB2

[0551] Knockdown results

[0552] The results were calculated using the 2^-ΔΔCt method, with the average of three tests taken. The results for knockdown of human hAQP1 RNA and human hADRB2 RNA are shown in Table 7 below.

[0553] Table 7. Results of editing human hAQP1 and hADRB2 RNA using the C13-2 system

[0554] The data in Table 8 show that compared with the negative control, the experimental group can significantly reduce the expression levels of hAQP1 RNA and hADRB2 RNA at the same time.

[0555] Example 3: In vivo animal efficacy test

[0556] The C13-2-ADRB2-gRNA10 plasmid of Example 1 and the aforementioned control plasmid C13-2-Luc were used.

[0557] A three-plasmid system containing the C13-2-ADRB2-gRNA10 plasmid was transfected into 293T cells using a three-plasmid method to isolate serotype AAV-ShH10, which expresses C13-2 and gRNA10. A separate AAV-ShH10 expressing C13-2 and gRNA-Luc was prepared using the same method.

[0558] Thirty-two normal 6-week-old C57 mice with stable intraocular pressure were selected. Sixteen mice in the negative control group were injected intracamerally (IC) with gRNA-Luc AAV (2×10 10GC AAV), and 16 mice in the experimental group were injected with gRNA10AAV (2×10 10 GC AAV).

[0559] At 2, 4, 6, 7, and 8 weeks after administration, use TONOLAB tonometer measures intraocular pressure.

[0560] Results showed that from week 6 to week 8, the gRNA10 group significantly reduced intraocular pressure in mice compared to the negative control group (P<0.01). Therefore, the gRNA10+C13-2 combination has the potential to be used in the treatment of glaucoma, with long-term efficacy (the IOP-lowering effect lasts for at least 2 weeks) and low dosing frequency, which will bring great convenience when used as a drug.

[0561] Example 4: In vivo animal efficacy test

[0562] The previous examples showed that gRNA 18 had a high editing efficiency, so we continued to design gRNAs 18-2 and 18-3, which are adjacent to the target sequence. As shown in Figure 6, the nucleotide sequences in the figure are SEQ ID NOs: 711 and 712, and the amino acid sequence is SEQ ID NO: 713.

[0563] Table 8. New gRNAs designed based on gRNA18

[0564] Using the methods of Example 1 and Example 2, the editing efficiency of the combination of CasRx and the new gRNA in human 293T cells overexpressing hADRB2 was determined in the same batch of experiments, as shown in Table 9 below.

[0565] Table 9. Editing effects of new gRNAs designed based on gRNA18

[0566] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be considered as equivalent replacement methods and are included in the scope of protection of the present invention.

Claims

1. Use of a gene editing system in the preparation of a drug for diagnosing, treating or preventing glaucoma, wherein the gene editing system: (I) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA; or (II) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA, and knocking down the level of AQP1 RNA or inhibiting the translation of AQP1 RNA.

2. The use according to claim 1, wherein the gene editing system include: (I) a first guide RNA comprising a guide sequence that hybridizes to ADRB2 RNA or a polynucleotide sequence encoding the first guide RNA, and an RNA-guided first nuclease or a polynucleotide sequence encoding the RNA-guided first nuclease, and optional (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease; The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA; The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

3. The use according to claim 1, wherein the ADRB2 RNA is mammalian mRNA; and / or The AQP1 RNA is mammalian pre-mRNA and / or mature mRNA.

4. The use according to claim 2, wherein the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and / or the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

5. The use according to claim 2, wherein after the first complex contacts a cell containing ADRB2 RNA, the level of the ADRB2 RNA or ADRB2 protein in the cell is reduced by at least 5%; and / or After the second complex is contacted with a cell containing AQP1 RNA, the level of the AQP1 RNA or AQP1 protein in the cell is reduced by at least 5%.

6. The use according to claim 2, wherein the guide sequence of the first guide RNA has at least 80% sequence identity with nucleotides 1 to 2013, or nucleotides 222 to 1463 of the sequence shown in SEQ ID NO:

684.

7. The use according to claim 2, wherein the guide sequence of the second guide RNA has at least 80% sequence identity with nucleotides 1 to 2754, or nucleotides 58 to 867 of SEQ ID NO:

703.

8. The use according to claim 2, wherein the guide sequence of the first guide RNA has at least 80% sequence identity with the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

9. The use according to claim 2, wherein the guide sequence of the second guide RNA has at least 80% sequence identity with the sequence shown in SEQ ID NO:

704.

10. The use according to claim 2, wherein the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with a first nuclease guided by RNA; and / or The second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with a second nuclease guided by the RNA.

11. The use according to claim 2, wherein the first nuclease guided by the RNA is a Cas protein; optionally, the first nuclease guided by the RNA is a Cas9 protein, a Cas12 protein or a Cas13 protein; further optionally, the first nuclease guided by the RNA is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein or a Cas13j protein.

12. The use according to claim 2, wherein the second nuclease guided by the RNA is a Cas protein; optionally, the second nuclease guided by the RNA is a Cas9 protein, a Cas12 protein or a Cas13 protein; further optionally, the second nuclease guided by the RNA is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein or a Cas13j protein.

13. The use according to claim 2, wherein the first guide RNA is capable of forming a first complex with the first RNA-guided nuclease and guiding the complex to bind to and cleave ADRB2 RNA; and / or The second guide RNA is capable of forming a second complex with an RNA-guided second nuclease and directing the complex to bind to and cleave AQP1 RNA.

14. The use according to claim 2, wherein the first RNA-guided nuclease is the same as or different from the second RNA-guided nuclease.

15. The use according to claim 2, wherein the RNA-guided first nuclease and / or the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation inhibition domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

16. The use according to claim 2, wherein the first nuclease guided by RNA comprises a nuclear localization signal and / or a nuclear export signal sequence; and / or The RNA-guided second nuclease comprises a nuclear localization signal and / or a nuclear export signal sequence.

17. The use according to claim 2, wherein the polynucleotide sequence encoding the first nuclease guided by the RNA is connected to the regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to the regulatory sequence 2 that regulates its expression; and / or The polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

18. The use according to claim 2, wherein the regulatory sequence 1 regulating the expression of the first nuclease guided by the RNA is the same as or different from the regulatory sequence 3 regulating the expression of the second nuclease guided by the RNA; and / or The regulatory sequence 2 that regulates the expression of the first guide RNA is the same as or different from the regulatory sequence 4 that regulates the expression of the second guide RNA.

19. A gene editing system, It is characterized in that The gene editing system: (I) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA; or (II) knocking down the level of ADRB2 RNA or inhibiting the translation of ADRB2 RNA, and knocking down the level of AQP1 RNA or inhibiting the translation of AQP1 RNA.

20. The gene editing system according to claim 19, include: (I) a first guide RNA comprising a guide sequence that hybridizes with ADRB2 RNA or a polynucleotide encoding the first guide RNA an acid sequence, and a first RNA-guided nuclease or a polynucleotide sequence encoding the first RNA-guided nuclease, and optional (II) a second guide RNA comprising a guide sequence that hybridizes to AQP1 RNA or a polynucleotide sequence encoding the second guide RNA, and an RNA-guided second nuclease or a polynucleotide sequence encoding the RNA-guided second nuclease; The first guide RNA is capable of forming a first complex with the first nuclease and guiding the complex to sequence-specific binding to ADRB2 RNA; The second guide RNA is capable of forming a second complex with the second nuclease and directing sequence-specific binding of the complex to AQP1 RNA.

21. The gene editing system of claim 19, wherein the ADRB2 RNA is mammalian mRNA; and / or The AQP1 RNA is mammalian pre-mRNA or mature mRNA.

22. The gene editing system of claim 20, wherein the first guide RNA guides the first complex to bind to and cleave the ADRB2 RNA, and / or the second guide RNA guides the second complex to bind to and cleave the AQP1 RNA.

23. The gene editing system of claim 20, wherein after the first complex contacts a cell containing ADRB2 RNA, the level of the ADRB2 RNA or ADRB2 protein in the cell is reduced by at least 5%; and / or After the second complex is contacted with a cell containing AQP1 RNA, the level of the AQP1 RNA or AQP1 protein in the cell is reduced by at least 5%.

24. The gene editing system of claim 20, wherein the guide sequence of the first guide RNA has at least 80% sequence identity with nucleotides 1 to 2013, or nucleotides 222 to 1463 of the sequence shown in SEQ ID NO:

684.

25. The gene editing system of claim 20, wherein the guide sequence of the second guide RNA has at least 80% sequence identity with nucleotides 1 to 2754, or nucleotides 58 to 867 of SEQ ID NO:

703.

26. The gene editing system of claim 20, wherein the guide sequence of the first guide RNA has at least 80% sequence identity with the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

27. The gene editing system of claim 20, wherein the guide sequence of the second guide RNA has at least 80% sequence identity with the sequence shown in SEQ ID NO:

704.

28. The gene editing system of claim 20, wherein the first guide RNA comprises a first guide sequence and a first direct repeat sequence, and the first direct repeat sequence interacts with a first nuclease guided by the RNA; and / or The second guide RNA comprises a second guide sequence and a second direct repeat sequence, and the second direct repeat sequence interacts with a second nuclease guided by the RNA.

29. In the gene editing system of claim 20, the first nuclease guided by the RNA is a Cas protein; optionally, the first nuclease guided by the RNA is a Cas9 protein, a Cas12 protein or a Cas13 protein; further optionally, the first nuclease guided by the RNA is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein or a Cas13j protein.

30. In the gene editing system of claim 20, the second nuclease guided by RNA is a Cas protein; optionally, the second nuclease guided by RNA is a Cas9 protein, a Cas12 protein or a Cas13 protein; further optionally, the second nuclease guided by RNA is a Cas13a protein, a Cas13b protein, a Cas13c protein, a Cas13d protein or a Cas13j protein.

31. The gene editing system of claim 20, wherein the first guide RNA is capable of forming a first complex with the RNA-guided first nuclease and directing the complex to bind to and cleave ADRB2 RNA; and / or The second guide RNA is capable of forming a second complex with an RNA-guided second nuclease and directing the complex to bind to and cleave AQP1 RNA.

32. The gene editing system of claim 20, wherein the RNA-guided first nuclease is the same as or different from the RNA-guided second nuclease.

33. The use according to claim 2, wherein the RNA-guided first nuclease and / or the RNA-guided second nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation inhibition domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

34. The gene editing system of claim 20, wherein the RNA-guided first nuclease comprises a nuclear localization signal and / or a nuclear export signal sequence; and / or The RNA-guided second nuclease comprises a nuclear localization signal and / or a nuclear export signal sequence.

35. The gene editing system of claim 20, wherein the polynucleotide sequence encoding the first RNA-guided nuclease is connected to a regulatory sequence 1 that regulates its expression, and the polynucleotide sequence encoding the first guide RNA is connected to a regulatory sequence 2 that regulates its expression; and / or The polynucleotide sequence encoding the second nuclease guided by the RNA is connected to the regulatory sequence 3 that regulates its expression, and the polynucleotide sequence encoding the second guide RNA is connected to the regulatory sequence 4 that regulates its expression.

36. The gene editing system of claim 20, wherein the regulatory sequence 1 regulating the expression of the first RNA-guided nuclease is the same as or different from the regulatory sequence 3 regulating the expression of the second RNA-guided nuclease; and / or The regulatory sequence 2 that regulates the expression of the first guide RNA is the same as or different from the regulatory sequence 4 that regulates the expression of the second guide RNA.

37. The gene editing system of claim 35, wherein the regulatory sequence is a promoter sequence and / or an enhancer sequence.

38. The gene editing system of claim 35, wherein the regulatory sequence is selected from a CMV promoter, a CMV enhancer, a CBh promoter, a U6 promoter, and an eye-specific promoter.

39. The gene editing system of claim 20, which can be introduced into a cell or a cell-free system in any of the following ways: (i) as mRNA encoding an RNA-guided nuclease and a guide RNA, (ii) as part of a single vector or plasmid, or divided into multiple vectors or plasmids, (iii) as separate RNA-guided nucleases and guide RNAs, or (iv) as an RNP complex of an RNA-guided nuclease and a guide RNA.

40. A gene editing system guide RNA, It is characterized in that It contains a guide sequence that hybridizes to ADRB2 RNA.

41. The guide RNA of claim 40, wherein the ADRB2 RNA is a mammalian mRNA.

42. The guide RNA of claim 40, wherein the ADRB2 RNA is human ADRB2 mRNA.

43. The guide RNA of claim 40, wherein the ADRB2 RNA comprises the sequence shown in SEQ ID NO:

684.

44. The guide RNA of claim 40, wherein the guide sequence has at least 80% sequence identity to the ADRB2 RNA.

45. The guide RNA of claim 40, wherein the guide sequence has at least 80% sequence identity with nucleotides 1 to 2013, or nucleotides 222 to 1463 of the sequence shown in SEQ ID NO:

684.

46. ​​The guide RNA of claim 40, wherein the guide sequence has at least 80% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-683, 709-710.

47. The guide RNA of claim 40, which is capable of forming a complex with an RNA-guided nuclease and directing sequence-specific binding of the complex to ADRB2 RNA.

48. The guide RNA of claim 40, which is capable of forming a complex with the nuclease and directing the complex to bind to and cleave the ADRB2 RNA.

49. The guide RNA of claim 47 or 48, wherein the complex reduces the level of the ADRB2 RNA in a mammal.

50. The guide RNA of claim 47 or 48, wherein upon contact of the complex with a cell comprising ADRB2 RNA, the level of the ADRB2 RNA in the cell is reduced by at least 5%.

51. The guide RNA of claim 49, wherein the reduction in the level of ADRB2 RNA is tested using a qPCR method, untreated cells or cells treated with a gene editing system targeting a non-mammalian genome are used as negative controls, and the level of ADRB2 RNA knockdown in the experimental group compared to the negative control is calculated.

52. The guide RNA of claim 47 or 48, wherein after the complex is contacted with a cell comprising ADRB2 RNA, the level of protein encoded by the ADRB2 RNA in the cell is reduced.

53. The guide RNA of claim 47 or 48, wherein upon contact of the complex with a cell comprising ADRB2 RNA, the level of ADRB2 protein in the cell is reduced by at least 5%.

54. The guide RNA as described in claim 52 is used to test the reduction of the level of protein encoded by the ADRB2 RNA using ELISA or Western Blotting method, and untreated cells or cells treated with a gene editing system targeting a non-mammalian genome are used as negative controls, and the knockdown level of ADRB2 protein in the experimental group is calculated compared with that in the negative control group.

55. The guide RNA of claim 40, comprising a guide sequence and a direct repeat sequence that interacts with an RNA-guided nuclease.

56. An isolated nucleic acid, It is characterized in that It encodes the guide RNA according to any one of claims 40-55.

57. A vector comprising a polynucleotide sequence encoding the guide RNA according to any one of claims 40 to 55, and a regulatory sequence for regulating the expression of the guide RNA.

58. A vector system, in, The vector system comprises a polynucleotide sequence encoding the guide RNA according to any one of claims 40 to 55 and a second regulatory sequence that regulates the expression of the guide RNA; and a polynucleotide sequence encoding an RNA-guided nuclease and a first regulatory sequence that regulates the expression of the RNA-guided nuclease.

59. The vector system of claim 58, comprising one or more vectors.

60. The vector system of claim 58, wherein the regulatory sequence is a promoter sequence and / or an enhancer sequence.

61. An adeno-associated virus vector, It is characterized in that The adeno-associated viral vector comprises DNA encoding an RNA-guided nuclease and a guide RNA according to any one of claims 40-55.

62. A lipid nanoparticle, It is characterized in that The lipid nanoparticle comprises the guide RNA according to any one of claims 40-55 and an mRNA encoding the RNA-guided nuclease.

63. A lentiviral vector, It is characterized in that The lentiviral vector comprises the guide RNA according to any one of claims 40-55 and an mRNA encoding an RNA-guided nuclease.

64. The lentiviral vector of claim 63, wherein the lentiviral vector is pseudotyped with an envelope protein; optionally, the mRNA encoding the RNA-guided nuclease is linked to an aptamer sequence.

65. A ribonucleoprotein complex, It is characterized in that The ribonucleoprotein complex is formed by the guide RNA according to any one of claims 40-55 and the RNA-guided nuclease.

66. A virus-like particle, It is characterized in that The virus-like particle comprises a ribonucleoprotein complex formed by the guide RNA according to any one of claims 40-55 and an RNA-guided nuclease.

67. The virus-like particle of claim 66, wherein the RNA-guided nuclease is fused to the gag protein.

68. A eukaryotic cell, It is characterized in that The eukaryotic cell comprises a gene editing system according to any one of claims 19-39, a guide RNA according to any one of claims 40-55, a nucleic acid according to claim 56, a vector according to any one of claims 57, or a vector system according to any one of claims 58-60.

69. The eukaryotic cell of claim 68, which is a mammalian cell.

70. A pharmaceutical composition, It is characterized in that It comprises the gene editing system according to any one of claims 19-39, the guide RNA according to any one of claims 40-55, the nucleic acid according to claim 56, the vector according to any one of claims 57, or the vector system according to any one of claims 58-60.

71. The pharmaceutical composition of claim 70, comprising a pharmaceutically acceptable excipient.

72. Use of the guide RNA according to any one of claims 40-55, the nucleic acid according to claim 56, the vector according to any one of claims 57, or the vector system according to any one of claims 58-60, the adeno-associated virus vector according to claim 61, the lipid nanoparticle according to claim 62, the lentiviral vector according to claim 63 or 64, the ribonucleoprotein complex according to claim 65, the virus-like particle according to claim 66 or 67, the eukaryotic cell according to claim 68 or 69, or the pharmaceutical composition according to claim 70 or 71 in any of the following or in the preparation of an agent for implementing any of the following schemes: Cut or nick one or more ADRB2 RNA molecules, activate or upregulate one or more ADRB2 RNAs, activate or inhibit translation of one or more ADRB2 RNA molecules, inactivate one or more ADRB2 RNA molecules, visualize, label or detect one or more ADRB2 RNA molecules, bind one or more ADRB2 RNA molecules, transport one or more ADRB2 RNA molecules, and mask one or more ADRB2 RNA molecules.

73. Use of the guide RNA according to any one of claims 40-55, the nucleic acid according to claim 56, the vector according to any one of claims 57, or the vector system according to any one of claims 58-60, the adeno-associated virus vector according to claim 61, the lipid nanoparticle according to claim 62, the lentiviral vector according to claim 63 or 64, the ribonucleoprotein complex according to claim 65, the virus-like particle according to claim 66 or 67, the eukaryotic cell according to claim 68 or 69, or the pharmaceutical composition according to claim 70 or 71 in any of the following or in the preparation of an agent for implementing any of the following schemes: Cleaves ADRB2 RNA molecules, inhibits translation of ADRB2 RNA molecules, and binds to ADRB2 RNA molecules.

74. The use according to claim 72 or 73, wherein the target RNA is mammalian ADRB2 mRNA.

75. The use according to claim 72 or 73, wherein the target RNA is human ADRB2 mRNA.

76. A method of diagnosing, treating or preventing a disease or condition, It is characterized in that An effective amount of the gene editing system according to any one of claims 19-39, the guide RNA according to any one of claims 40-55, the nucleic acid according to claim 56, the vector according to any one of claims 57, or the vector system according to any one of claims 58-60, the adeno-associated virus vector according to claim 61, the lipid nanoparticle according to claim 62, the lentiviral vector according to claim 63 or 64, the ribonucleoprotein complex according to claim 65, the virus-like particle according to claim 66 or 67, the eukaryotic cell according to claim 68 or 69, or the pharmaceutical composition according to claim 70 or 71 is administered to a sample of a subject in need or to a subject in need.

77. The method of claim 76, wherein the disease or condition is a disease or condition associated with ADRB2 RNA; alternatively, the disease or condition is a disease or condition caused by abnormally high expression of ADRB2 RNA; further alternatively, the disease or condition is a disease or condition caused by abnormally high expression of ADRB2 RNA and AQP1 RNA.

78. The method of claim 76, wherein the ADRB2 RNA is human ADRB2 mRNA, and / or the AQP1 RNA is pre-mRNA or mRNA.

79. The method of claim 76, wherein the ADRB2 RNA is human ADRB2 mRNA and the AQP1 RNA is human mature AQP1 mRNA.

80. The method of claim 76, wherein the disease or condition include: glaucoma.

Citation Information

Patent Citations

  • Four sgRNAs designed by aiming at human source ADRB2 genes

    CN108546703A

  • Non-pigmented ciliary epithelial cell specific promoters

    CN114765991A

  • SgRNA for targeted destruction of Aqp1 mRNA, and vector and application thereof

    CN114908090A

  • Separated Cas13 protein and application thereof

    CN116083398A

  • siRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions

    US20150259677A1